var title_f43_42_44704="SLS MRS";
var content_f43_42_44704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Brain MRI and MR spectroscopy (MRS) of a 5 year old with Sjogren-Larsson syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) Image shows voxel locations in the occipital trigone (Box A) and in the central occipital gray matter (Box B).",
"    <br>",
"     Panel B) Proton MR spectra (TE = 20 msec) obtained from cerebral white matter (Spectrum C) and gray matter (Spectrum D). Note the presence of the high, sharp lipid peak at 1.3 ppm and a small peak at 0.8 to 0.9 ppm in the spectrum obtained from the white matter.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Willemsen MA, Van Der Graaf M, Van Der Knaap MS, et al. MR imaging and proton MR spectroscopic studies in Sjogren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 2004; 25:649. Copyright &copy;2004 American Society of Neuroradiology.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44704=[""].join("\n");
var outline_f43_42_44704=null;
var title_f43_42_44705="Calculator: Community-acquired pneumonia severity index (PSI) for adults";
var content_f43_42_44705=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"CommunityAcqPneumonia_form\" name=\"CommunityAcqPneumonia_form\" onkeydown=\"document.AAGradient_form.cctotal.value='';\" onkeyup=\"CommunityAcqPneumonia_fx();\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Community-acquired pneumonia severity index (PSI) for adults",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Sex",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           M (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           F (-10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Demographic factors",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onchange=\"CommunityAcqPneumonia_fx();\" onfocus=\"this.value=''; document.$eqform.cctotal.value='';\" size=\"6\" type=\"text\" value=\"\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Age (1 point for each year)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Nursing home resident (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Comorbid illnesses",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Neoplastic disease (30 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Liver disease (20 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Heart failure (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Cerebrovascular disease (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Renal disease (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Physical examination findings",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Altered mental status (20 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Respiratory rate &gt;=30/minute (20 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc11\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Systolic blood pressure &lt;90 mmHg (20 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc12\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Temperature &lt;35&deg;C or &gt;=40&deg;C (15 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc13\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Pulse &gt;=125/minute (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Laboratory and radiographic findings",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc14\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Arterial pH &lt;7.35 (30 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc15\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Blood urea nitrogen &gt;=30 mg/dL (11 mmol/L) (20 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc16\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Sodium &lt;130 mEq/L (20 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc17\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Glucose &gt;=250 mg/dL (14 mmol/L) (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc18\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Hematocrit &lt;30 percent (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc19\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Partial pressure of arterial oxygen &lt;60 mmHg or oxygen saturation &lt;90 percent (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc20\" onclick=\"CommunityAcqPneumonia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Pleural effusion (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          Pneumonia Score Interpretation",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0-50 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Class I 0.1% Mortality",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           51-70 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Class II 0.6% Mortality",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           71-90 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Class III 0.9% Mortality",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_4\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           91-130 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Class IV 9.3% Mortality",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_5\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           131-395 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Class V 27.0% Mortality",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Fine MJ, Auble TE, Yealy DM, et. al. A prediction rule to identify low-risk patients with community-acquired pneumonia.",
"        <i>",
"         N Engl J Med",
"        </i>",
"        . 1997; 336:243-250.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"CommunityAcqPneumonia_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44705=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function CommunityAcqPneumonia_fx() {",
"with(document.CommunityAcqPneumonia_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 0;",
"}",
"if (cc1[1].checked){",
"Score = Score + -10;",
"}",
"thisvalue = parseFloat(cc2.value);",
"if (isNaN(thisvalue)) thisvalue = 0;",
"ThisScore =  thisvalue * 1 + 0;",
"Score =  Score + ThisScore;",
"if (cc3.checked){",
"Score = Score + 10;",
"}",
"if (cc4.checked){",
"Score = Score + 30;",
"}",
"if (cc5.checked){",
"Score = Score + 20;",
"}",
"if (cc6.checked){",
"Score = Score + 10;",
"}",
"if (cc7.checked){",
"Score = Score + 10;",
"}",
"if (cc8.checked){",
"Score = Score + 10;",
"}",
"if (cc9.checked){",
"Score = Score + 20;",
"}",
"if (cc10.checked){",
"Score = Score + 20;",
"}",
"if (cc11.checked){",
"Score = Score + 20;",
"}",
"if (cc12.checked){",
"Score = Score + 15;",
"}",
"if (cc13.checked){",
"Score = Score + 10;",
"}",
"if (cc14.checked){",
"Score = Score + 30;",
"}",
"if (cc15.checked){",
"Score = Score + 20;",
"}",
"if (cc16.checked){",
"Score = Score + 20;",
"}",
"if (cc17.checked){",
"Score = Score + 10;",
"}",
"if (cc18.checked){",
"Score = Score + 10;",
"}",
"if (cc19.checked){",
"Score = Score + 10;",
"}",
"if (cc20.checked){",
"Score = Score + 10;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if ((Score >= 0) && (Score <= 50)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >= 51) && (Score <= 70)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Score >= 71) && (Score <= 90)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if ((Score >= 91) && (Score <= 130)){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"if ((Score >= 131) && (Score <= 395)){ document.getElementById('rr1_5').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"document.getElementById('rr1_5').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f43_42_44705=null;
var title_f43_42_44706="Patient information: Liver cancer (The Basics)";
var content_f43_42_44706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16838\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/54/40804\">",
"         Organs inside the abdomen (belly)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/25/24979\">",
"         Patient information: Cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/27/17842\">",
"         Patient information: Hair loss from cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/34/25122\">",
"         Patient information: Liver transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/3/44084\">",
"         Patient information: Cirrhosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/39/4721\">",
"         Patient information: Liver biopsy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Liver cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/liver-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25892859\">",
"      <span class=\"h1\">",
"       What is liver cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Liver cancer happens when normal cells in the liver change into abnormal cells and grow out of control. The liver is a big organ in the upper right side of the belly (",
"      <a class=\"graphic graphic_figure graphicRef64960 \" href=\"mobipreview.htm?39/54/40804\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Most people who get liver cancer have long-term liver disease (also called chronic liver disease). Having long-term liver disease increases a person&rsquo;s chances of getting liver cancer. The most serious form of long-term liver disease is a condition called &ldquo;cirrhosis,&rdquo; which scars the liver.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25892874\">",
"      <span class=\"h1\">",
"       What are the symptoms of liver cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Liver cancer does not usually cause any symptoms of its own. A few patients might have a lump or mild pain in the upper belly, or feel full early on when they try to eat.",
"     </p>",
"     <p>",
"      Others may have symptoms that are caused by the liver disease they had before they got cancer. Those symptoms can get worse or come back because of the cancer. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swelling of the belly or legs",
"       </li>",
"       <li>",
"        The skin or white part of the eyes turning yellow",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have these symptoms, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25892889\">",
"      <span class=\"h1\">",
"       Is there a test for liver cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor suspects you have liver cancer, he or she will do 1 or more of the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        An MRI scan, CT scan, ultrasound, or other imaging test &ndash; Imaging tests create pictures of the inside of the body and can show abnormal growths.",
"       </li>",
"       <li>",
"        Biopsy &ndash; For this test, a doctor will remove a small sample of tissue from the liver. Another doctor will look at the sample under a microscope to see if it has cancer.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25892904\">",
"      <span class=\"h1\">",
"       What is liver cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out if a cancer has spread past the layer of tissue where it began and, if so, how far.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25892919\">",
"      <span class=\"h1\">",
"       How is liver cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Liver cancer can be treated in different ways. Treatment depends on the stage of your cancer and how healthy your liver is. The different treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery &ndash; Liver cancer can sometimes be treated with surgery to remove the part of the liver with the cancer.",
"       </li>",
"       <li>",
"        Liver transplant &ndash; A liver transplant is a type of surgery in which a doctor replaces a diseased liver with a healthy liver.",
"       </li>",
"       <li>",
"        Ablation therapy &ndash; Ablation therapy is a procedure that can kill cancer cells in the liver. It does not involve surgery. Doctors can do ablation therapy in different ways. They can kill the cancer cells using heat, a laser, or by injecting a special alcohol or acid directly into the cancer.",
"       </li>",
"       <li>",
"        Blocking the cancer&rsquo;s blood supply &ndash; Doctors can do a procedure called &ldquo;embolization&rdquo; to block off the blood vessel that sends blood to the cancer. This keeps the cancer from growing.",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells.",
"       </li>",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25892934\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will be checked every so often to see if the cancer comes back. Regular follow up tests usually include exams, blood tests, and imaging tests.",
"     </p>",
"     <p>",
"      You should also watch for the symptoms listed above. Having those symptoms could mean the cancer has come back. Tell your doctor or nurse if you have any symptoms.",
"     </p>",
"     <p>",
"      If you had a liver transplant, you will need to take medicines called &ldquo;anti-rejection medicines&rdquo; for the rest of your life. These medicines help keep your body from reacting badly to your new liver.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25892949\">",
"      <span class=\"h1\">",
"       What happens if the cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the cancer comes back or spreads, your doctor will talk with you about possible treatment choices. These might include the treatments listed above.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25892964\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for liver cancer involves making many choices, such as what treatment to have.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25892979\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/25/24979?source=see_link\">",
"       Patient information: Cirrhosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=see_link\">",
"       Patient information: Hair loss from cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/34/25122?source=see_link\">",
"       Patient information: Liver transplant (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/39/4721?source=see_link\">",
"       Patient information: Liver biopsy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44084?source=see_link\">",
"       Patient information: Cirrhosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?43/42/44706?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16838 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-109.230.63.219-37932DBF7B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44706=[""].join("\n");
var outline_f43_42_44706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25892859\">",
"      What is liver cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25892874\">",
"      What are the symptoms of liver cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25892889\">",
"      Is there a test for liver cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25892904\">",
"      What is liver cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25892919\">",
"      How is liver cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25892934\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25892949\">",
"      What happens if the cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25892964\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25892979\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16838\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/54/40804\">",
"      Organs inside the abdomen (belly)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44084?source=related_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/39/4721?source=related_link\">",
"      Patient information: Liver biopsy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/34/25122?source=related_link\">",
"      Patient information: Liver transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_42_44707="Thoracic aortic aneurysm plain chest film";
var content_f43_42_44707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thoracic aortic aneurysm plain chest film",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain frontal chest radiograph demonstrates marked aneurysmal dilatation of the entire arch of the aorta (arrows). Patency of the aorta or dissection within the lumen cannot be inferred from the plain film and contrast or echocardiographic studies are required to make this distinction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44707=[""].join("\n");
var outline_f43_42_44707=null;
var title_f43_42_44708="Endometrial ablation or resection: Resectoscopic techniques";
var content_f43_42_44708=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endometrial ablation or resection: Resectoscopic techniques",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44708/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44708/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44708/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44708/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44708/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44708/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/42/44708/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial ablation is a minimally invasive option for the treatment of abnormal uterine bleeding. Resectoscopic techniques are performed under hysteroscopic visualization, using resectoscopic instruments to ablate or resect the endometrium. These techniques are also referred to as standard or first generation ablation. Non-resectoscopic endometrial ablation is performed with a device that is inserted into the uterine cavity and delivers energy to uniformly destroy the uterine lining.",
"   </p>",
"   <p>",
"    Resectoscopic techniques for endometrial ablation will be reviewed here. General principles (eg, indications, contraindications, preoperative and postoperative care) of endometrial ablation, techniques for non-resectoscopic endometrial ablation, as well as other management options for abnormal uterine bleeding, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31866?source=see_link\">",
"     \"An overview of endometrial ablation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/24/393?source=see_link\">",
"     \"Endometrial ablation: Non-resectoscopic techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20122?source=see_link\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF RESECTOSCOPIC ABLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resectoscopic ablation is done under hysteroscopic visualization and requires the use of a resectoscope (",
"    <a class=\"graphic graphic_picture graphicRef74123 \" href=\"mobipreview.htm?32/50/33572\">",
"     picture 1",
"    </a>",
"    ). There are currently four techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44708/abstract/1\">",
"     1",
"    </a>",
"    ]: (1) endometrial dessication with an electrosurgical rollerball or rollerbarrel (",
"    <a class=\"graphic graphic_picture graphicRef55853 \" href=\"mobipreview.htm?14/35/14901\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44708/abstract/2\">",
"     2",
"    </a>",
"    ]; (2) resection with a monopolar or bipolar loop electrode (",
"    <a class=\"graphic graphic_picture graphicRef55853 \" href=\"mobipreview.htm?14/35/14901\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44708/abstract/3\">",
"     3",
"    </a>",
"    ]; (3) radiofrequency vaporization; or (4) laser vaporization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44708/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All methods dessicate the endometrium to the level of the basalis. The rollerball and rollerbarrel use thermal energy for heating the tissue to a temperature between 60 to 90&ordm;C, which dessicates and destroys the tissue. No tissue is removed. Thermal energy is also used with the monopolar and bipolar loop electrodes. However, the loop electrodes also resect the endometrium beyond the basalis layer to the myometrium. The resected tissue is sent to pathology for histologic diagnosis.",
"   </p>",
"   <p>",
"    The vaporizing electrodes and laser fibers use high energy to rapidly heat the intracellular water to 100&ordm;C, causing vaporization of tissue. No tissue is removed.",
"   </p>",
"   <p>",
"    Rollerball endometrial ablation is the most commonly used resectoscopic ablation method. Wire loop endomyometrial resection requires advanced hysteroscopic skills because of the risk of perforation, bleeding, and fluid absorption. Laser and vaporizing electrode ablation are not commonly performed due to expense of the equipment these methods require.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ROLLERBALL OR ROLLERBARREL OPERATIVE TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;General perioperative practices (eg, endometrial preparation, prophylactic antibiotics) and complications of endometrial ablation, as well as comparison with non-resectoscopic endometrial ablation, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31866?source=see_link&amp;anchor=H33#H33\">",
"     \"An overview of endometrial ablation\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31866?source=see_link&amp;anchor=H40#H40\">",
"     \"An overview of endometrial ablation\", section on 'Non-resectoscopic versus resectoscopic ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Instrumentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rollerball (or rollerbarrel) endometrial ablation is usually performed using monopolar electrical energy. Typically, the radiofrequency generator is set to 50 to 80 watts of coagulation or cutting current in order to desiccate the endometrium. We prefer cutting current, since coagulation current may result in vaginal burns caused by arching and capacitance coupling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44708/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, a bipolar resectoscope can be used. The advantage of a bipolar system is that saline is used, rather than electrolyte-free hypoconductive fluid. Excessive absorption of hypoconductive fluids (eg, glycine) may result in hyponatremia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8858?source=see_link\">",
"     \"Hyponatremia following transurethral resection or hysteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positioning, sterile preparation, and cervical dilation are the same as for hysteroscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of hysteroscopy\", section on 'Procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insert the resectoscope through the cervix.",
"     </li>",
"     <li>",
"      After distension with fluid, inspect the uterine cavity. Note the size and location of intracavitary lesions (eg, fibroids, polyps).",
"     </li>",
"     <li>",
"      Position the rollerball at one of the uterine cornu. It is helpful to start the desiccation at the cornua and then move to the anterior fundal wall due to bubble formation in the uterine cavity. Complete the ablation on the posterior wall since the bubbles formed will be anterior. Activate the current and bring the rollerball towards the surgeon. To avoid injury, it is important to keep the rollerball in view at all times and activate it only when moving it towards the operator. Desiccating the endometrium to a depth of 5 to 6 mm ensures the endometrium is destroyed to the level of the basalis (",
"      <a class=\"graphic graphic_figure graphicRef54487 \" href=\"mobipreview.htm?43/27/44465\">",
"       figure 1",
"      </a>",
"      ) and is unlikely to regenerate in the presence of reproductive hormones. A thin endometrium will be quickly dessicated to this level. When the myometrium is reached, the surgeon will note small bubbles forming around the leading edge of the rollerball. Avoid dessication of the cervico-uterine junction since this may result in cervical stenosis or uterine occlusion.",
"     </li>",
"     <li>",
"      Repeat this motion until the entire surface of the endometrium has been desiccated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Women with leiomyomas or polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resectoscopic endometrial ablation can be performed in women with submucosal leiomyomas. Women who have a submucosal leiomyoma in the uterine cavity can have a hysteroscopic myomectomy followed by endometrial ablation. This concurrent procedure is limited by the amount of irrigation fluid absorbed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8858?source=see_link\">",
"     \"Hyponatremia following transurethral resection or hysteroscopy\"",
"    </a>",
"    .) It is uncertain whether this procedure is more effective at improving uterine bleeding symptoms than myomectomy alone. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32601?source=see_link&amp;anchor=H30#H30\">",
"     \"Hysteroscopic myomectomy\", section on 'Concomitant procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endometrial polyps can be easily removed prior to ablation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7336?source=see_link\">",
"     \"Endometrial polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women undergoing resectoscopic endometrial ablation, we suggest rollerball endometrial ablation rather than wire loop endomyometrial resection, unless it is advantageous to send tissue for histology. Outcomes appear similar for these two techniques, but wire loop resection requires more surgical skill. Laser and vaporizing electrode ablation are not commonly performed due to expense of the equipment. The outcomes for resectoscopic endometrial ablation are discussed here. Complication rates of endometrial ablation and comparison of resectoscopic with non-resectoscopic ablation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31866?source=see_link&amp;anchor=H33#H33\">",
"     \"An overview of endometrial ablation\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31866?source=see_link&amp;anchor=H40#H40\">",
"     \"An overview of endometrial ablation\", section on 'Non-resectoscopic versus resectoscopic ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with successful endometrial ablation will have a reduction in uterine blood flow, but not amenorrhea. Studies vary according to whether menstrual blood loss is measured and the method used (eg, alkaline hematin method, pictorial blood assessment chart). Thus, amenorrhea, patient satisfaction, and subsequent surgery are used more commonly to assess treatment success than volume of uterine bleeding.",
"   </p>",
"   <p>",
"    The best available data regarding resectoscopic ablation are in a meta-analysis of 21 randomized trials (",
"    <a class=\"graphic graphic_table graphicRef71119 \" href=\"mobipreview.htm?3/40/3725\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44708/abstract/6\">",
"     6",
"    </a>",
"    ]. Major findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of amenorrhea at one year was 38 percent and at two to five years was 48 percent.",
"     </li>",
"     <li>",
"      The patient satisfaction rate at one year was 88 percent and at two to five years was 87 percent.",
"     </li>",
"     <li>",
"      Regarding subsequent surgery, the rate for any type of surgery (including hysterectomy) was 25 percent and for hysterectomy alone was 19 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Comparison among resectoscopic techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the meta-analysis, 5 of the 21 randomized trials compared between two resectoscopic endometrial ablation methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44708/abstract/6\">",
"     6",
"    </a>",
"    ]. Comparison of rollerball, vaporizing electrode, and laser methods with endomyometrial resection showed no significant differences in rates of reduced menstrual bleeding, amenorrhea, or subsequent hysterectomy. Similarly, there was no significant difference in complications between ablation and resection; one study found a significant increase in irrigation fluid deficit (an additional 258 mL) with endomyometrial resection compared with vaporizing electrode. Some, but not all, trials found that resection had a longer operative duration than other types of resectoscopic ablation. The study with the longest follow-up was a randomized trial (not included in the meta-analysis) of 120 women assigned to either rollerball ablation or wire loop resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44708/abstract/7\">",
"     7",
"    </a>",
"    ]. At 10-year follow-up, 93 percent of women in the study were amenorrheic. Women treated with other types of resectoscopic ablation compared with resection had the following rates of subsequent surgery: repeat ablation (13 versus 8 percent) and hysterectomy (25 versus percent 19); tests of significance were not reported.",
"   </p>",
"   <p>",
"    General complications of resectoscopic and non-resectoscopic endometrial ablation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31866?source=see_link&amp;anchor=H33#H33\">",
"     \"An overview of endometrial ablation\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H678785\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative care and other follow-up issues for endometrial ablation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31866?source=see_link&amp;anchor=H51#H51\">",
"     \"An overview of endometrial ablation\", section on 'Follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/8/143?source=see_link\">",
"       \"Patient information: Endometrial ablation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resectoscopic endometrial ablation is a treatment for abnormal uterine bleeding that is performed under hysteroscopic visualization, using resectoscopic instruments to ablate or resect the endometrium. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resectoscopic ablation currently uses one of four techniques: endometrial dessication with an electrosurgical rollerball or vaporizing electrode, laser endometrial desiccation, and endomyometrial resection using a wire loop. Rollerball endometrial ablation is the most commonly used resectoscopic method. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of resectoscopic ablation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rollerball endometrial ablation can be performed with either a monopolar or bipolar resectoscope. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Instrumentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resectoscopic endometrial ablation can be performed in women with small submucosal leiomyomas. Many surgeons remove the myoma prior to performing the ablation. Endometrial polyps can be easily removed prior to ablation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7336?source=see_link\">",
"       \"Endometrial polyps\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H6\">",
"       'Women with leiomyomas or polyps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All four methods of resectoscopic endometrial ablation have similar efficacy. Endometrial resection compared with other methods requires more surgical skill, has a longer operative duration, and may result in an increased absorption of irrigation fluid. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing resectoscopic endometrial ablation, we suggest rollerball endometrial ablation rather than wire loop endomyometrial resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Resection is preferred in women in whom tissue is needed for histologic evaluation. Laser and vaporizing electrode ablation are not commonly performed. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44708/abstract/1\">",
"      Munro MG. Endometrial ablation: where have we been? Where are we going? Clin Obstet Gynecol 2006; 49:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44708/abstract/2\">",
"      Vancaillie TG. Electrocoagulation of the endometrium with the ball-end resectoscope. Obstet Gynecol 1989; 74:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44708/abstract/3\">",
"      DeCherney A, Polan ML. Hysteroscopic management of intrauterine lesions and intractable uterine bleeding. Obstet Gynecol 1983; 61:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44708/abstract/4\">",
"      Goldrath MH, Fuller TA, Segal S. Laser photovaporization of endometrium for the treatment of menorrhagia. Am J Obstet Gynecol 1981; 140:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44708/abstract/5\">",
"      Munro MG. Mechanisms of thermal injury to the lower genital tract with radiofrequency resectoscopic surgery. J Minim Invasive Gynecol 2006; 13:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44708/abstract/6\">",
"      Lethaby A, Hickey M, Garry R, Penninx J. Endometrial resection / ablation techniques for heavy menstrual bleeding. Cochrane Database Syst Rev 2009; :CD001501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44708/abstract/7\">",
"      F&uuml;rst SN, Philipsen T, Joergensen JC. Ten-year follow-up of endometrial ablation. Acta Obstet Gynecol Scand 2007; 86:334.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3317 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44708=[""].join("\n");
var outline_f43_42_44708=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF RESECTOSCOPIC ABLATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ROLLERBALL OR ROLLERBARREL OPERATIVE TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Instrumentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Women with leiomyomas or polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Comparison among resectoscopic techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H678785\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3317\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3317|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/27/44465\" title=\"figure 1\">",
"      Endometrium layers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3317|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/50/33572\" title=\"picture 1\">",
"      Resectoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/35/14901\" title=\"picture 2\">",
"      Resectoscope instruments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3317|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/40/3725\" title=\"table 1\">",
"      Outcome of endometrial ablation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31866?source=related_link\">",
"      An overview of endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/24/393?source=related_link\">",
"      Endometrial ablation: Non-resectoscopic techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8858?source=related_link\">",
"      Hyponatremia following transurethral resection or hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32601?source=related_link\">",
"      Hysteroscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/8/143?source=related_link\">",
"      Patient information: Endometrial ablation (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_42_44709="Sorafenib: Patient drug information";
var content_f43_42_44709=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sorafenib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     see \"Sorafenib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2307883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NexAVAR&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6826164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nexavar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702950",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sorafenib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a heart problem called congenital QT syndrome, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697228",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a recent heart attack, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697737",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug and for at least 2 weeks after stopping the drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698220",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low white blood cell count or low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3001761",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Redness or irritation of the palms of hands or soles of feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Heart disease may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698154",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Holes in the GI (gastrointestinal) tract may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3448742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may put tablets in",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        4",
"       </sub>",
"       glass of water. Let it sit for 5 minutes, mix, and drink. Rinse glass with more water and drink.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11575 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44709=[""].join("\n");
var outline_f43_42_44709=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307883\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6826164\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025319\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025321\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025320\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025325\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025326\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025328\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025323\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025324\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025329\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025330\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=related_link\">",
"      Sorafenib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_42_44710="Vibrio vulnificus infections";
var content_f43_42_44710=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vibrio vulnificus infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44710/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44710/contributors\">",
"     J Glenn Morris, Jr, MD, MPH&amp;TM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44710/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44710/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44710/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44710/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/42/44710/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vibrio vulnificus is a gram-negative bacterium that can cause serious wound infections, septicemia, and diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. It is the leading cause of shellfish-associated deaths in the United States. Infections due to V. vulnificus are most common in individuals who have chronic, underlying illness; individuals with liver disease or hemochromatosis are at greatest risk.",
"   </p>",
"   <p>",
"    The pathogenesis, epidemiology, clinical features, diagnosis, and treatment of V. vulnificus infections will be reviewed here. The disease cholera, caused by \"epidemic\" strains of Vibrio cholerae, infections caused by Vibrio parahaemolyticus, and illnesses associated with other Vibrio strains and species are discussed separately. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36073?source=see_link\">",
"     \"Overview of Vibrio cholerae infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/14/27878?source=see_link\">",
"     \"Vibrio parahaemolyticus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18502?source=see_link\">",
"     \"Infections due to non-O1/O139 Vibrio cholerae\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. vulnificus exists as a free-living bacterium inhabiting estuarine or marine environments. Three biotypes are recognized: biotype 1, which accounts for almost all human infections; biotype 2, which consists primarily of eel pathogens; and biotype 3, an apparent hybrid of biotypes 1 and 2 that has been described in tilapia-associated wound infections in Israel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    V. vulnificus accounts for approximately 8 percent of the aerobic bacteria in the Chesapeake Bay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/5\">",
"     5",
"    </a>",
"    ]. Counts peak during summer and late fall, when water temperatures are highest. Filter-feeding shellfish such as oysters concentrate bacteria and may have counts of V. vulnificus up to two orders of magnitude greater than those in the surrounding water. V. vulnificus can be isolated from virtually all oysters harvested in the Chesapeake Bay and the United States Gulf Coast when water temperatures exceed 20&ordm;C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Over 90 percent of patients with \"primary\" V. vulnificus septicemia (ie, septicemia without an obvious source such as a wound) report having consumed raw oysters prior to the onset of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wound infections generally result from exposure of a wound to salt or brackish water containing the organism, and most often occur in the setting of handling seafood or in association with recreational water activities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As with oyster or other food vehicle associated infections, wound infections are most common during warm summer months. In August and September 2005 after Hurricane Katrina, 14 V. vulnificus wound-associated illnesses were identified; three patients died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/10\">",
"     10",
"    </a>",
"    ]. Most of these cases occurred among individuals with predisposing medical conditions and wounds exposed to flood waters.",
"   </p>",
"   <p>",
"    Wound infections and bacteremia have been reported due to biogroup 3 strains associated with injuries sustained while handling live tilapia fish from aquaculture ponds in Israel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/4,11,12\">",
"     4,11,12",
"    </a>",
"    ]. Initial reports of illness were linked with unusually high temperatures in the region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with the following conditions are at increased risk for serious infection with V. vulnificus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/2,8,14\">",
"     2,8,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcoholic cirrhosis (present in 31 to 43 percent of patients with primary septicemia)",
"     </li>",
"     <li>",
"      Underlying liver disease including cirrhosis and chronic hepatitis (24 to 31 percent of patients)",
"     </li>",
"     <li>",
"      Alcohol abuse without documented liver disease (12 to 27 percent of patients)",
"     </li>",
"     <li>",
"      Hereditary hemochromatosis (12 percent of patients)",
"     </li>",
"     <li>",
"      Chronic diseases such as diabetes mellitus, rheumatoid arthritis, thalassemia major, chronic renal failure, and lymphoma (7 to 8 percent of patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In population-based studies in coastal areas in the United States, the estimated incidence of V. vulnificus infections is approximately",
"    <span class=\"nowrap\">",
"     0.5/100,000",
"    </span>",
"    population per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The estimated national incidence, based on reports to surveillance programs, is substantially lower at 0.04 to 0.05 per 100,000 persons per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/18\">",
"     18",
"    </a>",
"    ]. However, this rate has increased dramatically since 1996.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virulence of V. vulnificus has been associated with three major factors: (1) production of an anti-phagocytic polysaccharide capsule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/19\">",
"     19",
"    </a>",
"    ]; (2) the RtxA toxin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/20\">",
"     20",
"    </a>",
"    ]; and (3) iron availability and iron acquisition systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Capsule",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. vulnificus produces a capsular polysaccharide that provides protection against phagocytosis and opsonization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/19\">",
"     19",
"    </a>",
"    ]. Strains are able to undergo phase variation, shifting between encapsulated forms (opaque colony morphology) and unencapsulated forms (translucent colony morphology). Unencapsulated strains are avirulent in mouse models. When these strains are taken up by oysters, there is a high rate of shift to the capsulated phenotype, suggesting that oyster passage selects for the encapsulated, virulent form of the organism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anticapsular antibodies are protective, but appear to be type-specific rather than cross-reactive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/25\">",
"     25",
"    </a>",
"    ]. The type-specific nature of protective antibodies is significant since V. vulnificus has great diversity in capsular types. In one study of 120 strains, for example, 96 different capsular types (\"carbotypes\") were identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    V. vulnificus contains a lipopolysaccharide (LPS) but, in contrast to Escherichia coli and other members of the Enterobacteriaceae, the LPS of V. vulnificus is not a strong trigger for release of tumor necrosis factor (TNF)-alpha and other shock-related cytokines. However, capsular polysaccharide itself may directly trigger some cytokine responses, contributing to the development of the shock syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/27\">",
"     27",
"    </a>",
"    ]; TNF-alpha was detected in mice up to 12 hours after inoculation of an encapsulated V. vulnificus strain, while an unencapsulated strain was rapidly cleared. Both capsular polysaccharide and LPS provoked cytokine release in vitro from human peripheral blood mononuclear cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. vulnificus produces a variety of extracellular toxins, including both a hemolysin and protease, although deletion of these toxins from the bacterium does not affect virulence in mouse models.",
"   </p>",
"   <p>",
"    Virulence has been linked with RtxA1, a toxin homologous to the pore-forming RTX toxins found in Vibrio cholerae and other gram-negative bacteria. This toxin appears to act via Nox1 to induce significant reactive oxygen species generation in intestinal epithelial cells, leading to cell death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth of V. vulnificus is dependent in part upon the availability of iron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Growth of the organism in human serum is related directly to the percentage saturation of transferrin with iron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/21\">",
"     21",
"    </a>",
"    ]. When transferrin iron saturation exceeds 70 percent, growth of the bacterium is nearly exponential.",
"   </p>",
"   <p>",
"    The relationship between iron and virulence in V. vulnificus may account for the enhanced susceptibility to serious infections with this organism in patients with hemochromatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, most patients with serious V. vulnificus infections have normal iron and iron saturation levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations of hereditary hemochromatosis\", section on 'Susceptibility to specific infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differentiating strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of reported V. vulnificus cases is relatively low, in spite of the frequency with which humans are exposed to V. vulnificus in oysters and in contact with estuarine water (even taking into account differences in host susceptibility). This has led to the hypothesis that certain strain subsets are more likely than others to cause human disease. However, it has not been possible to identify a single V. vulnificus virulence factor that is almost exclusively present in clinical isolates (in contrast to V. parahaemolyticus).",
"   </p>",
"   <p>",
"    Certain carbotypes of V. vulnificus may be more likely than others to cause human illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/30\">",
"     30",
"    </a>",
"    ]. Clustering of human isolates within specific subgroups has also been noted based on ribotyping, pulsed field gel electrophoresis (PFGE), randomly amplified polymorphic DNA (RAPD) PCR techniques, and sequence polymorphism of 16S rRNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/31-34\">",
"     31-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. vulnificus causes wound infections and \"primary septicemia\" (septicemia without a clearly defined source of infection, such as a wound) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/1,2,8,14-16\">",
"     1,2,8,14-16",
"    </a>",
"    ]. Wound infections may be acquired during handling of shellfish or fish, or after exposure of a preexisting wound to estuarine water.",
"   </p>",
"   <p>",
"    V. vulnificus has also been associated with gastroenteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/35\">",
"     35",
"    </a>",
"    ]. An etiologic role is difficult to establish when the organism is isolated from stool samples since the bacterium is ubiquitous in both water and shellfish, and has been isolated from stool samples of asymptomatic persons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Wound infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. vulnificus may contaminate wounds exposed to estuarine waters, shellfish, or fish. Typical examples include hand injuries related to opening oysters or leg lacerations related to entering, exiting, or launching boats. The cellulitis is usually mild. However, in high-risk individuals, the infection may spread rapidly, producing severe myositis and fasciitis reminiscent of gas gangrene (",
"    <a class=\"graphic graphic_picture graphicRef55001 \" href=\"mobipreview.htm?42/37/43615\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Primary septicemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary V. vulnificus septicemia is associated with ingestion of raw or undercooked shellfish, particularly raw oysters. Patients with primary septicemia generally have underlying liver disease, alcoholism, hereditary hemochromatosis, or a chronic disease as noted above.",
"   </p>",
"   <p>",
"    Approximately one-third of patients with primary septicemia present in shock or become hypotensive within 12 hours of hospital admission. Three-fourths of patients have distinctive bullous skin lesions (",
"    <a class=\"graphic graphic_picture graphicRef63423 \" href=\"mobipreview.htm?31/11/31921\">",
"     picture 2",
"    </a>",
"    ). Thrombocytopenia is common, and often there is evidence of disseminated intravascular coagulation. Complications such as gastrointestinal bleeding can occur.",
"   </p>",
"   <p>",
"    Primary V. vulnificus septicemia is a serious illness with a high mortality rate. Among all reported foodborne infections in the United States, V. vulnificus is associated with the highest case fatality rate (39 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/36\">",
"     36",
"    </a>",
"    ]. Mortality rates exceeding 40 percent have been reported in case series, with a case fatality rate of more than 90 percent among those who are hypotensive when they present for medical care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/2,8,14,37\">",
"     2,8,14,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persons who survive the acute shock event often require prolonged hospitalization in intensive care, with complications resulting from multiorgan system failure. While there may be complete recovery from the actual V. vulnificus infection, there may be ongoing morbidity due to associated organ system failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the potential severity of the infection, a presumptive diagnosis of V. vulnificus septicemia should be made in any person with fever, hypotension, or symptoms suggestive of septic shock, characteristic bullous skin lesions, and risk factors for acquiring infection as noted above. The infection should also be suspected in persons from these risk groups who have rapidly progressive wound infections associated with exposure to estuarine waters.",
"   </p>",
"   <p>",
"    The diagnosis is confirmed by culture. V. vulnificus will grow without difficulty in standard blood culture media or on nonselective media (such as blood agar) routinely used for wound cultures; identification and speciation of the organism is possible via any standard, commercially available microbiology identification system.",
"   </p>",
"   <p>",
"    Isolation of the organism from stool generally requires the use of a specific selective culture media (thiosulfate citrate bile-salts sucrose [TCBS]), on which V. vulnificus, V. parahaemolyticus, and some other Vibrio species produce blue-green colonies, in contrast to the yellow colonies produced by V. cholerae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case fatality rates for V. vulnificus septicemia and serious wound infections have been shown to increase with greater delays between onset of illness and initiation of antibiotic treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/8,15\">",
"     8,15",
"    </a>",
"    ]. Thus, patients with a presumptive diagnosis of V. vulnificus septicemia should be started immediately on antibiotic therapy and managed aggressively in an intensive care unit to minimize the possible consequences of hypotension, septic shock, and the risk of multiorgan system failure.",
"   </p>",
"   <p>",
"    A retrospective study including 93 patients with V. vulnificus septicemia and hemorrhagic bullous cutaneous lesions suggested that combination antibiotic therapy with a third-generation cephalosporin and a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    more effectively reduced mortality than treatment with a first- or second-generation cephalosporin plus an aminoglycoside (odds ratio 0.04; 95% CI, 0.01-0.19) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/37\">",
"     37",
"    </a>",
"    ]. Similarly, in a retrospective study of 89 patients with histologically and microbiologically confirmed V. vulnificus necrotizing fasciitis who underwent prompt surgical debridement, those treated with either a third-generation cephalosporin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    with or without minocycline had lower mortality rates than those who received a third-generation cephalosporin alone (14, 14, and 61 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro and in vivo studies in mice have demonstrated an apparent synergism between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    in the treatment of serious V. vulnificus infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/39\">",
"     39",
"    </a>",
"    ]. Subsequent studies showed comparable survival in mice treated with fluoroquinolones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these data, we favor treatment of patients with septicemia or serious wound infections using combination therapy with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally twice daily) plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    (2 g intravenously every eight hours) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 g intravenously daily); with doses appropriately adjusted for underlying renal or hepatic disease. A reasonable alternative is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg orally or intravenously once daily).",
"   </p>",
"   <p>",
"    Mild wound infections in patients who do not have significant underlying diseases generally respond well to local care and oral antibiotics (such as a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    or a fluoroquinolone). In high-risk patients, more serious wound infections may require aggressive debridement in addition to parenteral antibiotics. In a series of 4754 infections, 10 percent of patients required amputation of some type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/8\">",
"     8",
"    </a>",
"    ]. Duration of therapy is dictated by clinical response; most patients respond to 5 to 7 days of antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high mortality associated with V. vulnificus infection, individuals in high-risk groups should avoid eating raw or undercooked shellfish, particularly oysters. Post-harvest treatments (mild heat treatment, freezing, hydrostatic pressure) can reduce V. vulnificus counts in raw oysters, potentially reducing disease risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44710/abstract/41\">",
"     41",
"    </a>",
"    ]. Individuals with increased susceptibility to V. vulnificus infections should also avoid situations in which estuarine-associated wounds are likely to occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3115889\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vibrio vulnificus is a gram-negative bacterium that can cause serious wound infections, septicemia, and diarrhea. It is the leading cause of shellfish-associated deaths in the United States. Serious infections due to V. vulnificus are most common in individuals who have chronic, underlying illness; those with liver disease or hemochromatosis are at greatest risk. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      V. vulnificus can be isolated from virtually all oysters harvested in the Chesapeake Bay and the United States Gulf Coast when water temperatures exceed 20&ordm;C. Over 90 percent of patients with \"primary\" V. vulnificus septicemia (ie, septicemia without an obvious source such as a wound) report having consumed raw oysters prior to the onset of illness. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Growth of V. vulnificus in human serum is related to the percentage saturation of transferrin with iron. The relationship between iron and virulence in V. vulnificus may account for the enhanced susceptibility to serious infections in patients with hemochromatosis. However, most patients with serious V. vulnificus infections have normal iron and iron saturation levels. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Iron'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wound infections generally result from exposure of a wound to salt or brackish water containing the organism, and most often occur in the setting of handling seafood or in association with recreational water activities. In high-risk individuals, the infection may spread rapidly, producing severe myositis and fasciitis reminiscent of gas gangrene (",
"      <a class=\"graphic graphic_picture graphicRef55001 \" href=\"mobipreview.htm?42/37/43615\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Wound infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary V. vulnificus septicemia is a serious illness with a high mortality rate. Approximately one third of patients with primary septicemia present in shock or become hypotensive within 12 hours of hospital admission. Three-fourths of patients have distinctive bullous skin lesions (",
"      <a class=\"graphic graphic_picture graphicRef63423 \" href=\"mobipreview.htm?31/11/31921\">",
"       picture 2",
"      </a>",
"      ). Thrombocytopenia is common, and often there is evidence of disseminated intravascular coagulation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Primary septicemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A presumptive diagnosis of V. vulnificus septicemia should be made in any person with fever, hypotension, or symptoms of septic shock, characteristic bullous skin lesions, and risk factors for infection. The diagnosis is confirmed by culture; V. vulnificus will grow without difficulty in standard media. Isolation of the organism from stool generally requires the use of a specific selective culture media (thiosulfate citrate bile-salts sucrose [TCBS]). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a presumptive diagnosis of V. vulnificus septicemia should be started immediately on antibiotic therapy and managed aggressively in an intensive care unit. We suggest treatment with a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      plus a third-generation cephalosporin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Mild wound infections in patients who do not have significant underlying diseases generally respond well to local care and oral antibiotics; we suggest a tetracycline or fluoroquinolone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/1\">",
"      Morris JG Jr, Black RE. Cholera and other vibrioses in the United States. N Engl J Med 1985; 312:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/2\">",
"      Blake PA, Merson MH, Weaver RE, et al. Disease caused by a marine Vibrio. Clinical characteristics and epidemiology. N Engl J Med 1979; 300:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/3\">",
"      Daniels NA. Vibrio vulnificus oysters: pearls and perils. Clin Infect Dis 2011; 52:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/4\">",
"      Bisharat N, Cohen DI, Harding RM, et al. Hybrid Vibrio vulnificus. Emerg Infect Dis 2005; 11:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/5\">",
"      Wright AC, Hill RT, Johnson JA, et al. Distribution of Vibrio vulnificus in the Chesapeake Bay. Appl Environ Microbiol 1996; 62:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/6\">",
"      Motes ML, DePaola A, Cook DW, et al. Influence of water temperature and salinity on Vibrio vulnificus in Northern Gulf and Atlantic Coast oysters (Crassostrea virginica). Appl Environ Microbiol 1998; 64:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/7\">",
"      Jones MK, Oliver JD. Vibrio vulnificus: disease and pathogenesis. Infect Immun 2009; 77:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/8\">",
"      Dechet AM, Yu PA, Koram N, Painter J. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006. Clin Infect Dis 2008; 46:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/9\">",
"      Yoder JS, Hlavsa MC, Craun GF, et al. Surveillance for waterborne disease and outbreaks associated with recreational water use and other aquatic facility-associated health events--United States, 2005-2006. MMWR Surveill Summ 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Vibrio illnesses after Hurricane Katrina--multiple states, August-September 2005. MMWR Morb Mortal Wkly Rep 2005; 54:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/11\">",
"      Bisharat N, Agmon V, Finkelstein R, et al. Clinical, epidemiological, and microbiological features of Vibrio vulnificus biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel. Israel Vibrio Study Group. Lancet 1999; 354:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/12\">",
"      Broza YY, Danin-Poleg Y, Lerner L, et al. Epidemiologic study of Vibrio vulnificus infections by using variable number tandem repeats. Emerg Infect Dis 2009; 15:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/13\">",
"      Paz S, Bisharat N, Paz E, et al. Climate change and the emergence of Vibrio vulnificus disease in Israel. Environ Res 2007; 103:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/14\">",
"      Tacket CO, Brenner F, Blake PA. Clinical features and an epidemiological study of Vibrio vulnificus infections. J Infect Dis 1984; 149:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/15\">",
"      Klontz KC, Lieb S, Schreiber M, et al. Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987. Ann Intern Med 1988; 109:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/16\">",
"      Johnston JM, Becker SF, McFarland LM. Vibrio vulnificus. Man and the sea. JAMA 1985; 253:2850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/17\">",
"      Hoge CW, Watsky D, Peeler RN, et al. Epidemiology and spectrum of Vibrio infections in a Chesapeake Bay community. J Infect Dis 1989; 160:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/18\">",
"      Newton A, Kendall M, Vugia DJ, et al. Increasing rates of vibriosis in the United States, 1996-2010: review of surveillance data from 2 systems. Clin Infect Dis 2012; 54 Suppl 5:S391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/19\">",
"      Wright AC, Simpson LM, Oliver JD, Morris JG Jr. Phenotypic evaluation of acapsular transposon mutants of Vibrio vulnificus. Infect Immun 1990; 58:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/20\">",
"      Chung KJ, Cho EJ, Kim MK, et al. RtxA1-induced expression of the small GTPase Rac2 plays a key role in the pathogenicity of Vibrio vulnificus. J Infect Dis 2010; 201:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/21\">",
"      Brennt CE, Wright AC, Dutta SK, Morris JG Jr. Growth of Vibrio vulnificus in serum from alcoholics: association with high transferrin iron saturation. J Infect Dis 1991; 164:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/22\">",
"      Kim CM, Park RY, Choi MH, et al. Ferrophilic characteristics of Vibrio vulnificus and potential usefulness of iron chelation therapy. J Infect Dis 2007; 195:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/23\">",
"      Kim CM, Park YJ, Shin SH. A widespread deferoxamine-mediated iron-uptake system in Vibrio vulnificus. J Infect Dis 2007; 196:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/24\">",
"      Srivastava M, Tucker MS, Gulig PA, Wright AC. Phase variation, capsular polysaccharide, pilus and flagella contribute to uptake of Vibrio vulnificus by the Eastern oyster (Crassostrea virginica). Environ Microbiol 2009; 11:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/25\">",
"      Devi SJ, Hayat U, Powell JL, Morris JG Jr. Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus. Infect Immun 1996; 64:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/26\">",
"      Bush CA, Patel P, Gunawardena S, et al. Classification of Vibrio vulnificus strains by the carbohydrate composition of their capsular polysaccharides. Anal Biochem 1997; 250:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/27\">",
"      Powell JL, Wright AC, Wasserman SS, et al. Release of tumor necrosis factor alpha in response to Vibrio vulnificus capsular polysaccharide in in vivo and in vitro models. Infect Immun 1997; 65:3713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/28\">",
"      Bullen JJ, Spalding PB, Ward CG, Gutteridge JM. Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch Intern Med 1991; 151:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/29\">",
"      Gerhard GS, Levin KA, Price Goldstein J, et al. Vibrio vulnificus septicemia in a patient with the hemochromatosis HFE C282Y mutation. Arch Pathol Lab Med 2001; 125:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/30\">",
"      Hayat U, Reddy GP, Bush CA, et al. Capsular types of Vibrio vulnificus: an analysis of strains from clinical and environmental sources. J Infect Dis 1993; 168:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/31\">",
"      Tamplin ML, Jackson JK, Buchrieser C, et al. Pulsed-field gel electrophoresis and ribotype profiles of clinical and environmental Vibrio vulnificus isolates. Appl Environ Microbiol 1996; 62:3572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/32\">",
"      Jackson JK, Murphree RL, Tamplin ML. Evidence that mortality from Vibrio vulnificus infection results from single strains among heterogeneous populations in shellfish. J Clin Microbiol 1997; 35:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/33\">",
"      Nilsson WB, Paranjype RN, DePaola A, Strom MS. Sequence polymorphism of the 16S rRNA gene of Vibrio vulnificus is a possible indicator of strain virulence. J Clin Microbiol 2003; 41:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/34\">",
"      Rosche TM, Yano Y, Oliver JD. A rapid and simple PCR analysis indicates there are two subgroups of Vibrio vulnificus which correlate with clinical or environmental isolation. Microbiol Immunol 2005; 49:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/35\">",
"      Johnston JM, Becker SF, McFarland LM. Gastroenteritis in patients with stool isolates of Vibrio vulnificus. Am J Med 1986; 80:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/36\">",
"      Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis 1999; 5:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/37\">",
"      Liu JW, Lee IK, Tang HJ, et al. Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch Intern Med 2006; 166:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/38\">",
"      Chen SC, Lee YT, Tsai SJ, et al. Antibiotic therapy for necrotizing fasciitis caused by Vibrio vulnificus: retrospective analysis of an 8 year period. J Antimicrob Chemother 2012; 67:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/39\">",
"      Chuang YC, Ko WC, Wang ST, et al. Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother 1998; 42:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/40\">",
"      Tang HJ, Chang MC, Ko WC, et al. In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus. Antimicrob Agents Chemother 2002; 46:3580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44710/abstract/41\">",
"      Depaola A, Jones JL, Noe KE, et al. Survey of postharvest-processed oysters in the United States for levels of Vibrio vulnificus and Vibrio parahaemolyticus. J Food Prot 2009; 72:2110.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3128 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.243-7F1A92C927-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44710=[""].join("\n");
var outline_f43_42_44710=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3115889\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Capsule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differentiating strains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Wound infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Primary septicemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3115889\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3128\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3128|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/37/43615\" title=\"picture 1\">",
"      Severe Vibrio vulnificus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/11/31921\" title=\"picture 2\">",
"      Bullous Vibrio vulnificus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18502?source=related_link\">",
"      Infections due to non-O1/O139 Vibrio cholerae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36073?source=related_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/14/27878?source=related_link\">",
"      Vibrio parahaemolyticus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_42_44711="Adjuvant immunotherapy for melanoma";
var content_f43_42_44711=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant immunotherapy for melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44711/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44711/contributors\">",
"     Jeffrey A Sosman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44711/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44711/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44711/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44711/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/42/44711/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision is the treatment of choice for early cutaneous melanoma and is curative in most cases. However, some patients will subsequently relapse with disseminated disease. High risk features in the primary tumor and regional lymph node metastasis define patient subsets that are at increased risk for recurrent disease.",
"   </p>",
"   <p>",
"    Adjuvant immunotherapy with interferon alfa (IFNa) prolongs disease-free and overall survival in selected patients at increased risk for disease dissemination. High dose IFNa continued for one year has become the standard of care for patients with resected node-positive melanoma (stage III) and should be considered for patients with negative nodes and an increased risk of recurrence (stage IIB and IIC (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"mobipreview.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    )).",
"   </p>",
"   <p>",
"    A number of other approaches have been studied to reduce the risk of recurrence in patients thought to be at high risk for relapse. These include adjuvant chemotherapy with agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], nonspecific immune adjuvants such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/30/28135?source=see_link\">",
"     Bacillus Calmette-Guerin (BCG) vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ], Corynebacterium parvum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], or levamisole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/8-10\">",
"     8-10",
"    </a>",
"    ], and hormonal agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    . However, none of these agents, used either alone or in various combinations, proved beneficial when compared to either observation or placebo in randomized clinical trials.",
"   </p>",
"   <p>",
"    The use of adjuvant immunotherapy with IFNa will be reviewed here, along with a brief discussion of experimental approaches to adjuvant therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2754350\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for the use of adjuvant IFNa as therapy following disease resection is based upon early clinical studies that demonstrated antitumor activity in patients with metastatic melanoma. Both animal model and histologic evidence suggest that the effects of IFNa are mediated through effects on host cells, rather than through a direct effect on tumor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a murine melanoma model, intact signaling pathways are necessary in the host immune system for IFNa to induce tumor regression; if these are not present, tumor growth is not inhibited by IFNa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast, an intact signaling pathway within the tumor was not required for tumor regression in response to IFNa.",
"   </p>",
"   <p>",
"    Additional evidence comes from a clinical research study, in which single-agent high dose IFNa was administered as a neoadjuvant for four weeks to patients with palpable regional lymphadenopathy; this was followed by a complete lymphadenectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/12\">",
"     12",
"    </a>",
"    ]. Tumor responses were documented in 11 of 20 patients (55 percent). Tumor samples from patients who responded to IFNa had increased numbers of CD11c and CD3 positive cells within their tumors and a decrease in the number of CD83 positive cells, compared to those who did not respond to IFNa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157827536\">",
"    <span class=\"h1\">",
"     CRITERIA FOR PATIENT SELECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157827371\">",
"    <span class=\"h2\">",
"     Staging and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent and characteristics of the primary tumor and regional lymph node involvement allow classification of patients into different risk categories. The TNM staging system of the American Joint Committee on Cancer (AJCC) (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"mobipreview.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ) incorporates the most important determinants of prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the primary tumor (T), increasing tumor thickness, an increased mitotic rate, and the presence of ulceration (ie, the loss of the epidermal layer overlying the primary tumor) are associated with an increased risk of relapse (",
"      <a class=\"graphic graphic_figure graphicRef53002 \" href=\"mobipreview.htm?11/60/12225\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The presence of lymph node involvement is associated with a significant increase in risk of recurrence, and this is further subdivided based upon the number and extent of lymph node disease (",
"      <a class=\"graphic graphic_figure graphicRef74483 \" href=\"mobipreview.htm?22/8/22656\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157827551\">",
"    <span class=\"h2\">",
"     Low risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients diagnosed with melanoma present with stage I or IIA disease (localized tumor either &le;4 mm in thickness without ulceration or &le;2 mm in thickness with ulceration). In these patients, surgery is usually curative, and adjuvant therapy is not indicated except in the context of a formal clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157827560\">",
"    <span class=\"h2\">",
"     High risk node negative (stage IIB or IIC) disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients without lymph node involvement but with high risk features in their primary tumor are at increased risk for recurrence and disease dissemination. High risk primary tumors include those with tumor &gt;4mm thick, ulceration, or a mitotic rate",
"    <span class=\"nowrap\">",
"     &ge;1/mm",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    Appropriate options thus include high dose IFNa for one year, observation, or inclusion in a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157827581\">",
"    <span class=\"h2\">",
"     Microscopic involvement of one lymph node",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage III disease based upon the present of microscopic involvement in only one lymph node are at higher risk than those without lymph node involvement, but are at lower risk than those with more extensive lymph node disease. Available evidence from clinical trials supports several options, including high dose IFNa for one year, pegylated IFN for five years, participation in a clinical trial, or observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157827594\">",
"    <span class=\"h2\">",
"     Macroscopic or multiple lymph node involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with more extensive lymph node disease, one year of adjuvant therapy with high dose IFNa is considered the standard approach for patients who are not enrolled in a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2754301\">",
"    <span class=\"h2\">",
"     Non-disease related criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high dose IFNa regimen for one year can be associated with significant side effects. (See",
"    <a class=\"local\" href=\"#H2754866\">",
"     'Treatment-related toxicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus patients who are being offered adjuvant IFNa should have a good performance status without significant depression or a history of psychiatric disorder. IFNa is also not appropriate for those with a history of an autoimmune disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of adjuvant immunotherapy with IFNa in patients considered to be at high risk for recurrence following their initial surgical resection is based upon the results of numerous clinical trials. These trials have used differing doses and schedules of IFNa, and the trials have varied in the definition of high risk for the patients that were included.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2754343\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most extensive data come from a meta-analysis that included data from 14 randomized trials published between 1990 and 2008, which included a total of 8122 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/15\">",
"     15",
"    </a>",
"    ]. In 12 of the 14 trials, patients were randomly assigned to IFNa and to either observation or placebo; in the other two trials, IFNa was compared with a GM2-KLH vaccine that was considered to be inactive.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease-free survival with IFNa was significantly prolonged overall (hazard ratio [HR] for recurrence 0.82, 95% CI 0.77-0.87). These results were consistent across different patient subsets or based upon the IFNa dose and schedule and there was no statistically significant heterogeneity between clinical trials.",
"     </li>",
"     <li>",
"      Overall survival (for which data was available for 12 of 14 trials) was significantly improved with IFNa (HR for death 0.89, 95% CI 0.83-0.96).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     High dose IFNa trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high dose schedule of IFNa has been the most widely used, and is generally considered the standard approach for patients who are to receive adjuvant IFNa. This has been extensively studied in multiple large cooperative group trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1491956492\">",
"    <span class=\"h3\">",
"     ECOG 1684",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Eastern Cooperative Oncology Group trial (ECOG 1684), 287 patients with melanomas &gt;4 mm in depth (stage IIB) or subclinical or clinically apparent regional node involvement (stage III) were randomly assigned to one year of high-dose (HD) IFNa-2b or close observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/16\">",
"     16",
"    </a>",
"    ]. The IFNa treatment schedule consisted of intravenous therapy at a dose of 20 million",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    five days per week for four weeks followed by 10 million",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    subcutaneously three times weekly for an additional 11 months.",
"   </p>",
"   <p>",
"    At a median follow-up of nearly seven years, the following statistically significant benefits were noted in the IFNa arm:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nine-month prolongation in relapse-free survival (RFS, median 1.7 versus 1.0 years), with an 11 percent absolute increase in RFS at five years (37 versus 26 percent)",
"     </li>",
"     <li>",
"      A one-year prolongation in median survival (3.8 versus 2.8 years), with a 9 percent absolute increase in survival at five years (46 versus 37 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent analysis, the improvement in overall survival was no longer statistically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/17\">",
"     17",
"    </a>",
"    ]. Treatment benefit appeared to be confined to patients with lymph node involvement, with a doubling of RFS in these subgroups. Although patients without nodal involvement (T4NO stage IIB, (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"mobipreview.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    )) did not appear to benefit, there were too few patients in this subgroup to make any meaningful assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1491956536\">",
"    <span class=\"h3\">",
"     Intergroup E1690",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Intergroup protocol E1690 compared high dose IFNa (as in the E1684 protocol), to low dose IFNa (as in the WHO 16 protocol), or observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/18\">",
"     18",
"    </a>",
"    ]. The eligibility criteria for this study were similar to those for ECOG 1684, except that patients with clinically normal regional nodes were not required to undergo staging lymph node dissections. As a result, approximately 25 percent of the 642 patients had deep primary tumors with undefined nodal status.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both the high dose IFNa and the observation arms had significantly better survival than was observed in the respective study populations treated in ECOG 1684. A subtle selection bias over time probably accounts for this \"study effect\".",
"     </li>",
"     <li>",
"      A significant RFS benefit was noted for high dose IFNa relative to observation (hazard ratio [HR] 1.28). This benefit was particularly large for patients with melanoma involving two to three lymph nodes. Low dose IFNa produced an intermediate result relative to observation (hazard ratio 1.19, p = 0.17).",
"     </li>",
"     <li>",
"      There was no overall survival benefit associated with high dose IFNa relative to either low dose IFNa or observation. It is uncertain why the RFS benefit observed with high dose IFNa failed to translate into an overall survival benefit. One contributing factor was the extraordinarily high salvage rate among patients relapsing off the observation arm. In a retrospective review of the data, many such patients were treated with further surgery and either IFNa or IL-2 containing regimens following relapse. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7625?source=see_link\">",
"       \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1491956543\">",
"    <span class=\"h3\">",
"     Intergroup E1694",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intergroup E1694 compared high dose IFNa-2b to the GM2-KLH vaccine in resected stage IIB and III melanoma patients, the same population studied in ECOG 1684 and 1690 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/19\">",
"     19",
"    </a>",
"    ]. The trial was closed prematurely when interim analysis disclosed a significantly worse RFS and overall survival for patients treated with the GM2-KLH vaccine compared to the high dose IFNa (hazard ratios HR 1.47 and 1.52, respectively).",
"   </p>",
"   <p>",
"    The initial interpretation of this trial was that the GM2-KLH vaccine was no worse than observation and that the vaccine thus served as a control group for the high dose IFNa. A subsequent trial found that the vaccine did not improve overall survival compared to observation alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7625?source=see_link&amp;anchor=H552585758#H552585758\">",
"     \"Interleukin-2 and other immunotherapies for advanced melanoma\", section on 'Ganglioside vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intermediate and low dose trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple trials have evaluated lower doses of adjuvant IFNa-2a or -2b either alone or in combination with IL-2 to determine whether similar effectiveness could be achieved with decreased toxicity and expense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. Although some of these trials demonstrated a benefit in RFS for the IFN arm relative to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/22\">",
"     22",
"    </a>",
"    ], particularly in patients with melanomas 1.5 to 4 mm thick, this benefit was lost once treatment stopped, raising the possibility that prolonged treatment may be necessary. Overall these trials have demonstrated either no benefit or less benefit than that seen with the high dose IFNa schedule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2754866\">",
"    <span class=\"h2\">",
"     Treatment-related toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of adjuvant high dose IFNa is associated with numerous adverse effects, including acute constitutional symptoms, chronic fatigue, myelosuppression, and neurologic and psychologic effects, which are experienced to some degree by the majority of patients (",
"    <a class=\"graphic graphic_table graphicRef71277 \" href=\"mobipreview.htm?0/63/1020\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Granulocytopenia occurs in the majority of patients and may be severe enough in 20 to 60 percent to warrant dose modification. Infections are uncommon, suggesting a different mechanism of myelosuppression than that seen with cytotoxic chemotherapy.",
"     </li>",
"     <li>",
"      Liver toxicity resulted in two early deaths in ECOG trial 1684, but has not been a cause of death in the United States cooperative group trials since vigilant monitoring and dose modification guidelines were mandated.",
"     </li>",
"     <li>",
"      Fatigue is common and was present in 70 to 100 percent of patients in large trials. Fatigue can increase in severity with duration of therapy and can be debilitating.",
"     </li>",
"     <li>",
"      Mild to moderate depression and impaired cognitive function are commonly reported, while mood instability (alternating mania and depression) occurs less often. A history of mood or psychiatric disorders is a risk factor for neuropsychiatric effects. The use of antidepressants (either therapeutically or prophylactically) may facilitate completion of the full planned course of therapy.",
"     </li>",
"     <li>",
"      Thyroid dysfunction (both hypothyroidism and hyperthyroidism) may appear during the course of IFNa therapy. It typically is autoimmune in nature and usually resolves within 6 to 12 months of stopping treatment. Studies suggest that thyroid dysfunction may be associated with a significantly enhanced chance of therapeutic benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients should be monitored closely during therapy. During the initial four week induction period with IFNa this should include weekly blood counts, liver function tests, and metabolic panels. These should then be repeated on a monthly basis for patients being treated on the high dose IFNa regimen.",
"   </p>",
"   <p>",
"    The majority of these effects can be managed with appropriate supportive care",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dose reduction if toxicity is severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/25\">",
"     25",
"    </a>",
"    ]. Most adverse reactions resolve with treatment discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Autoimmunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple manifestations of autoimmunity, including thyroid dysfunction, vitiligo, and the development of autoantibodies, occur in 15 to 30 percent of patients who are treated with IFNa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/26\">",
"     26",
"    </a>",
"    ]. Whether the immunotherapy can induce an autoimmune response and whether this is important for the development of an antitumor effect is uncertain, and different analyses have yielded conflicting results. The role that differences in IFN doses and schedules play in these disparate outcomes remains to be sorted out.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A direct relationship between the development of autoimmunity and the prevention of relapse in high-risk patients receiving adjuvant IFNa was supported by the results from a correlative study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/27\">",
"       27",
"      </a>",
"      ]. As part of a larger study, immunologic responses were assessed in 200 patients who were randomly assigned to induction therapy with IFNa for four weeks with or without maintenance therapy with IFNa for an additional 48 weeks. Overall, 52 patients (26 percent) developed antithyroid, antinuclear, or anticardiolipin autoantibodies or clinical manifestations of autoimmunity (eg, vitiligo, thyroiditis).",
"      <br/>",
"      <br/>",
"      The development of autoimmunity was associated with a striking improvement in both disease-free and overall survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/27\">",
"       27",
"      </a>",
"      ]. At a median follow-up of 46 months, patients with evidence of autoimmunity had statistically significant, marked reductions in the rate of relapse (13 versus 73 percent in those without autoimmunity) and of overall mortality (4 versus 54 percent). Multivariate analysis showed that the only independent prognostic factors were the development of autoimmunity and regional lymph node involvement at presentation; the specific treatment arm did not influence outcome. Similarly, in ECOG trials E2696 and E1694, the development of autoimmunity following IFNa therapy as manifested by the development of autoantibodies was associated with an improved outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a retrospective analysis of two randomized trials comparing intermediate dose interferon with observation found that the appearance of autoantibodies was not strongly associated with an improved relapse-free interval [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/29\">",
"       29",
"      </a>",
"      ]. This study analyzed 355 patients from EORTC 18952 and the Nordic Interferon trial, all of whom were negative for anticardiolipin, antithyroglobulin, and antinuclear antibodies at baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/20,30\">",
"       20,30",
"      </a>",
"      ]. Although the frequency of seroconversion increased with interferon treatment in both trials, the difference was not statistically significant when corrected for the duration of time patients were followed. Similarly, a subset analysis from EORTC 18991 trial of 220 patients who were autoantibody negative at treatment initiation found that the appearance of autoimmune antibodies was neither prognostic nor predictive for an improved outcome in patients treated with pegylated IFN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because autoimmunity may not be observed until months after the initiation of treatment, there is no way at present to identify prospectively those patients who are more likely to benefit from adjuvant IFNa, and alternative methods are needed to predict who will respond to adjuvant therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196087897\">",
"    <span class=\"h2\">",
"     Pegylated IFNa-2b",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pegylated IFNa has been developed to decrease the frequency with which IFNa is administered while maintaining a high level of exposure. Pegylated IFNa has been evaluated as an adjuvant following primary resection of melanoma in one phase III trial (EORTC 18991) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the EORTC 18991 trial, 1221 patients with stage III melanoma (N1 or N2 disease) were randomly assigned to pegylated IFNa or observation. The pegylated IFNa was given weekly for eight weeks (6",
"    <span class=\"nowrap\">",
"     microg/week",
"    </span>",
"    subcutaneously) and then as maintenance (3",
"    <span class=\"nowrap\">",
"     microg/week)",
"    </span>",
"    through five years. At a median follow-up of 7.6 years, the seven-year relapse-free survival was significantly increased with pegylated IFNa compared with observation (39.1 versus 34.6 percent; hazard ratio [HR], 0.87; 95% CI, 0.76 to 1.00; P = .055) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/32\">",
"     32",
"    </a>",
"    ]. There was no difference in overall survival (p = 0.57). The most frequent grade 3 or 4 side effects with pegylated IFNa were fatigue, hepatotoxicity, and depression (16, 11, and 6 percent of cases, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative approaches to high dose IFNa include combining IFNa with chemotherapy and the use of newer agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    ) that have been shown to increase survival in patients with metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157827639\">",
"    <span class=\"h2\">",
"     Adjuvant biochemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;IFN has been combined with IL-2 and various chemotherapy regimens, and biochemotherapy has been advocated as an alternative to high dose IFNa.",
"   </p>",
"   <p>",
"    This approach was studied in the randomized S-0008 trial, in which 402 evaluable patients with high risk melanoma were assigned to either high dose interferon for one year or biochemotherapy with three cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    , IL-2, and IFN, given every three weeks.",
"   </p>",
"   <p>",
"    Results from the trial were presented at the 2012 American Society of Clinical Oncology (ASCO) meeting based upon a median follow-up of over six years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapse-free survival (RFS) was significantly prolonged with biochemotherapy compared with high dose IFNa (five-year RFS 47 versus 39 percent, HR 0.76, 95% CI 0.58-0.98).",
"     </li>",
"     <li>",
"      However, there was no improvement in overall survival (five-year survival rate 56 percent on both treatment arms, HR 1.02, 95% CI 0.76-1.37).",
"     </li>",
"     <li>",
"      Biochemotherapy was associated with more grade 3 and 4 hematologic and gastrointestinal toxicity, but less hepatic and neuropsychiatric toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157827646\">",
"    <span class=\"h2\">",
"     Newer agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    , an anti-CTLA-4 monoclonal antibody, and molecularly targeted agents for patients with metastatic melanoma has led to the evaluation of these newer agents in an adjuvant setting for high-risk patients with melanoma. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=see_link\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19944?source=see_link\">",
"     \"Molecularly targeted therapy for metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There currently are no data to support the use of these agents in an adjuvant setting. However, several large phase III trials have been initiated or will be initiated shortly to assess the role of these and other approaches as an alternative to standard high-dose IFN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44711/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"       Ipilimumab",
"      </a>",
"      versus placebo (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT00636168?term=NCT00636168&amp;rank=1\">",
"       NCT00636168",
"      </a>",
"      ), which has completed accrual. Results are pending.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"       Ipilimumab",
"      </a>",
"      at two doses versus high dose interferon (ECOG 1609,",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT01274338&amp;Search=Search\">",
"       NCT01274338",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"       Vemurafenib",
"      </a>",
"      versus placebo (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT01667419&amp;Search=Search\">",
"       NCT01667419",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dabrafenib plus trametinib versus observation (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT01682083&amp;Search=Search\">",
"       NCT01682083",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pegylated interferon versus observation in patients with ulcerated melanoma &gt;1 mm (EORTC 18081,",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01502696?term=NCT01502696&amp;rank=1\">",
"       NCT01502696",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mage 3 vaccine versus placebo",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients should be encouraged to participate in clinical trials whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/6/28772?source=see_link\">",
"       \"Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/8/39042?source=see_link\">",
"       \"Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have undergone a definitive resection of cutaneous melanoma generally do well. However, subsets of patients at increased risk of recurrence can be defined based upon the characteristics of the primary tumor (thickness, mitotic rate, ulceration) or the presence of lymph node metastases. (See",
"      <a class=\"local\" href=\"#H157827536\">",
"       'Criteria for patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple clinical trials have demonstrated that adjuvant treatment with interferon alfa (IFNa) can prolong disease-free survival and overall survival in high risk groups, although such treatment can be associated with significant toxicity. Because of the potential for severe toxicity, adjuvant IFNa should be limited to patients with a good performance status, without significant depression or a psychiatric history, and without a history of autoimmune disease. (See",
"      <a class=\"local\" href=\"#H2754343\">",
"       'Meta-analysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2754866\">",
"       'Treatment-related toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients at low risk of recurrence (no lymph node involvement and tumor &le;4 mm in thickness without ulceration or &le;2 mm in thickness with ulceration, stage IIA (",
"      <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"mobipreview.htm?32/8/32910\">",
"       table 1A-B",
"      </a>",
"      )), we suggest not using adjuvant therapy since there a high probability of cure and there is no evidence that adjuvant therapy improves the prognosis. (See",
"      <a class=\"local\" href=\"#H157827551\">",
"       'Low risk patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with increased risk of recurrence based upon characteristics of the primary tumor (&gt;4 mm thick, the presence of ulceration, or a mitotic rate",
"      <span class=\"nowrap\">",
"       &ge;1/mm",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      but without lymph node metastases (stages IIB or IIC), we suggest adjuvant IFNa (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Alternative options include observation or participation in a clinical trial. (See",
"      <a class=\"local\" href=\"#H157827560\">",
"       'High risk node negative (stage IIB or IIC) disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2754343\">",
"       'Meta-analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with regional lymph node involvement (stage III), the extent of lymph node disease should be incorporated into the treatment recommendation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If disease is limited to microscopic involvement of a single lymph node (N1a disease), we suggest adjuvant IFNa (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Alternatives include observation or clinical trial participation. (See",
"      <a class=\"local\" href=\"#H157827581\">",
"       'Microscopic involvement of one lymph node'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2754343\">",
"       'Meta-analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If there is macroscopic involvement of a lymph node or if there is involvement of more than one node (N1b, N2, or N3 disease), we recommend adjuvant IFNa (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Alternatives include clinical trial participation, especially trials with an active control arm. (See",
"      <a class=\"local\" href=\"#H157827594\">",
"       'Macroscopic or multiple lymph node involvement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2754343\">",
"       'Meta-analysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are candidates for adjuvant IFNa, we suggest one year of therapy with the high dose schedule used in the Eastern Cooperative Oncology Group trial ECOG 1684 trial (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This trial used intravenous IFNa (20 million",
"      <span class=\"nowrap\">",
"       units/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      five days per week for four weeks) followed by 10 million",
"      <span class=\"nowrap\">",
"       units/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      subcutaneously three times weekly for an additional 11 months. Alternative schedules (lower doses, shorter duration of therapy, or in combination with other agents) have not been demonstrated to be equally effective and are not recommended. One large clinical study suggests that pegylated IFNa is an alternative for patients with lymph node involvement.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/1\">",
"      Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 307:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/2\">",
"      Karakousis CP, Emrich LJ. Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG. J Surg Oncol 1987; 36:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/3\">",
"      Banzet P, Jacquillat C, Civatte J, et al. Adjuvant chemotherapy in the management of primary malignant melanoma. Cancer 1978; 41:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/4\">",
"      Morton DL, Eilber FR, Holmes EC, et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 1974; 180:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/5\">",
"      Lipton A, Harvey HA, Lawrence B, et al. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Cancer 1983; 51:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/6\">",
"      Balch CM, Smalley RV, Bartolucci AA, et al. A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy. Cancer 1982; 49:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/7\">",
"      Lipton A, Harvey HA, Balch CM, et al. Corynebacterium parvum versus bacille Calmette-Gu&eacute;rin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol 1991; 9:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/8\">",
"      Loutfi A, Shakr A, Jerry M, et al. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 1987; 10:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/9\">",
"      Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991; 9:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/10\">",
"      Parkinson DR. Levamisole as adjuvant therapy for melanoma: quo vadis? J Clin Oncol 1991; 9:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/11\">",
"      Lesinski GB, Anghelina M, Zimmerer J, et al. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 2003; 112:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/12\">",
"      Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006; 24:3164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/13\">",
"      Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199.",
"     </a>",
"    </li>",
"    <li>",
"     Melanoma of the Skin. In: American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.325.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/15\">",
"      Sabel MS, Sondak VK. Point: Interferon-alpha for adjuvant therapy for melanoma patients. J Natl Compr Canc Netw 2004; 2:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/16\">",
"      Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/17\">",
"      Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/18\">",
"      Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18:2444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/19\">",
"      Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/20\">",
"      Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/21\">",
"      Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/22\">",
"      Grob JJ, Dreno B, de la Salmoni&egrave;re P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998; 351:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/23\">",
"      Hauschild A, Weichenthal M, Rass K, et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of &gt;= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol 2010; 28:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/24\">",
"      Eggermont AM, Suciu S, Testori A, et al. Long-Term Results of the Randomized Phase III Trial. J Clin Oncol.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/25\">",
"      Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008; 112:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/26\">",
"      Koon H, Atkins M. Autoimmunity and immunotherapy for cancer. N Engl J Med 2006; 354:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/27\">",
"      Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/28\">",
"      Krauze MT, Tarhini A, Gogas H, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol 2011; 33:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/29\">",
"      Bouwhuis MG, Suciu S, Collette S, et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 2009; 101:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/30\">",
"      Hansson, J, Aamdal, S, Bastholt, L, et al. Results of the Nordic randomized adjuvant trial of intermediate-dose interferon alfa-2b in high-risk melanoma. Eur J Cancer 2007; 6(suppl 5):4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/31\">",
"      Bouwhuis MG, Suciu S, Testori A, et al. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol 2010; 28:2460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44711/abstract/32\">",
"      Eggermont AM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 2012; 30:3810.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ (Accessed on June 08, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7615 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-E56BECDC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44711=[""].join("\n");
var outline_f43_42_44711=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2754350\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H157827536\">",
"      CRITERIA FOR PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H157827371\">",
"      Staging and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H157827551\">",
"      Low risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H157827560\">",
"      High risk node negative (stage IIB or IIC) disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H157827581\">",
"      Microscopic involvement of one lymph node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H157827594\">",
"      Macroscopic or multiple lymph node involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2754301\">",
"      Non-disease related criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2754343\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      High dose IFNa trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1491956492\">",
"      - ECOG 1684",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1491956536\">",
"      - Intergroup E1690",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1491956543\">",
"      - Intergroup E1694",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intermediate and low dose trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2754866\">",
"      Treatment-related toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H196087897\">",
"      Pegylated IFNa-2b",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EXPERIMENTAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H157827639\">",
"      Adjuvant biochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H157827646\">",
"      Newer agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7615\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7615|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/60/12225\" title=\"figure 1\">",
"      Melanoma - Impact of T stage on prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/8/22656\" title=\"figure 2\">",
"      Melanoma - Impact of lymph node involvement on prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7615|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/61/8157\" title=\"table 1A\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/20/35149\" title=\"table 1B\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/63/1020\" title=\"table 2\">",
"      Toxicity adjuvant IFN alfa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=related_link\">",
"      Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7625?source=related_link\">",
"      Interleukin-2 and other immunotherapies for advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/8/39042?source=related_link\">",
"      Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/6/28772?source=related_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42488?source=related_link\">",
"      Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_42_44712="Vasectomy and other vasal occlusion techniques for male contraception";
var content_f43_42_44712=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vasectomy and other vasal occlusion techniques for male contraception",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44712/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44712/contributors\">",
"     Anthony Viera, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44712/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44712/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44712/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44712/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/42/44712/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasectomy is the most effective mode of permanent male contraception, and the only method that is widely available. The techniques used for interruption or occlusion of the vas deferens are discussed here. An overview of vasectomy including patient counseling is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39893?source=see_link\">",
"     \"Overview of vasectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only effective method available for male contraception is vasectomy, which divides the vas deferens in a minor surgical procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/1\">",
"     1",
"    </a>",
"    ]. The procedure takes about 15 minutes and can be performed in an appropriately equipped office or ambulatory surgery center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/2\">",
"     2",
"    </a>",
"    ]. No-scalpel vasectomy is the preferred vasectomy technique in the United States (US) because of its lower complication rates, but it has yet to be adopted world-wide. Because reversal of vasectomy cannot be guaranteed, other methods of vasal occlusion are being investigated.",
"   </p>",
"   <p>",
"    Three techniques are used for interruption or occlusion of the vas deferens. This topic will focus primarily on vasectomy; vasal occlusion and vasal injection techniques have been described but are not in general use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vasal transection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasectomy involves transection of the vas deferens, and is typically performed in an outpatient setting with local anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Conventional vasectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional vasectomy approach involves bilateral scrotal incisions through which the vas deferens is mobilized and transected. This technique accounts for a small proportion of vasectomies performed in the US, but remains the most common technique in many other areas of the world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Vasectomy procedure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     No-scalpel vasectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The no-scalpel vasectomy technique was developed in China [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/4\">",
"     4",
"    </a>",
"    ]. Instead of incisions, a puncture is made through the scrotal skin overlying the vas deferens and widened only enough to externalize the vas deferens for transection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/5\">",
"     5",
"    </a>",
"    ]. The remainder of the procedure is performed in a similar fashion to the open incision method. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Vasectomy procedure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vasal occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasal occlusion with a plug (eg, 'Shug' or medical grade silicone rubber), requires microsurgery for implantation and later removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/1\">",
"     1",
"    </a>",
"    ]. Either a conventional open or no-scalpel technique may be used to isolate the vas deferens for the implantation of these devices. Surgical vasal occlusion procedures claim to produce reversible azoospermia without affecting spermatogenesis, but there are no human data on success rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vasal injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous methods can be used for injecting chemicals directly into the vas deferens to effect temporary (polymer) or permanent (sclerosing agents) occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/1,6-8\">",
"     1,6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One technique intended for permanent sterilization involves first injecting two dyes into the vas, using a different color for the left and right vas. Then, a sclerosing agent is then injected into the vas lumen distal to the previously injected dye. Successful occlusion is determined by having the patient void to see which, if any, dye is excreted in the urine. The chemicals required for this procedure are not available for use in the US.",
"   </p>",
"   <p>",
"    Another technique, reversible inhibition of sperm under guidance (RISUG) involves injection the non-sclerotic polymer, styrene maleic anhydride (SMA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. It is claimed to offer long-term contraception without adverse side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. The purported advantages of this method are that it provides long term contraception without the side effects associated with male hormonal contraception, and in contrast to the other techniques listed above, is reversible without surgery. Clinical trials are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SURGICAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of surgical anatomy is important to minimize complications (eg, hematoma) and perform the procedure in a timely fashion. Injury to the vessels of the spermatic cord can cause significant bleeding.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Innervation - The anterior scrotal skin and spermatic cord are innervated by fibers from the ilioinguinal nerve and genital branches of the genitofemoral nerve (",
"      <a class=\"graphic graphic_figure graphicRef72166 \" href=\"mobipreview.htm?0/8/129\">",
"       figure 1",
"      </a>",
"      ). Local blockade of these nerves provides adequate anesthesia for vasectomy.",
"     </li>",
"     <li>",
"      Layers of the scrotum - Just beneath the scrotal skin lies (from outermost to innermost) the dartos fascia and muscle, the external spermatic fascia, and the cremasteric fascia and muscle (",
"      <a class=\"graphic graphic_figure graphicRef72166 \" href=\"mobipreview.htm?0/8/129\">",
"       figure 1",
"      </a>",
"      ). The internal spermatic fascia is deep to these structures and covers the spermatic cord, which contains the vas deferens and vessels and nerves.",
"     </li>",
"     <li>",
"      Blood vessels - The spermatic cord also contains the deferential artery to the vas deferens which anastomoses with the testicular artery and the veins (pampiniform plexus) (",
"      <a class=\"graphic graphic_figure graphicRef72166 \" href=\"mobipreview.htm?0/8/129\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pampiniform plexus consists of 8 or 10 veins that lie adjacent the vas deferens and ultimately drain into the testicular vein. These veins are easily injured. Dilatation of the pampiniform plexus (termed varicocele) is a common abnormality and usually occurs on the left. A varicocele can make isolation of the vas deferens more difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATIENT COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who choose to undergo vasectomy should clearly understand that the goal of the procedure is permanent sterilization. Patient counseling is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39893?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of vasectomy\", section on 'Patient counseling'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding diathesis, or presence of a local anatomic abnormality (eg, varicocele, hydrocele, scrotal mass, cryptorchidism) are relative contraindications to vasectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/1\">",
"     1",
"    </a>",
"    ]. Contraindications to vasectomy include the presence of scrotal hematoma, genitourinary or groin infection, and sperm granuloma but the procedure can often be performed if these issues can be resolved .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to proceeding with the procedure, the patient should have a complete urologic evaluation to confirm the presence of a single vas deferens and testicle on each side and absence of anatomic abnormalities.",
"   </p>",
"   <p>",
"    Routine preoperative laboratory tests, prophylactic antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/10\">",
"     10",
"    </a>",
"    ], and fasting are unnecessary. The patient should be instructed to have someone available to drive him home after the procedure.",
"   </p>",
"   <p>",
"    Patients should avoid taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and non-steroidal anti-inflammatory medications for seven days prior to the procedure, as these may increase the risk of postoperative bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link&amp;anchor=H25#H25\">",
"     \"Perioperative medication management\", section on 'Medications affecting hemostasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An anxiolytic (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    10 mg orally) can be given approximately one hour prior to the procedure to help the patient relax. This also helps surgical isolation of the vas deferens as it facilitates relaxation of the scrotal and cremasteric muscles.",
"   </p>",
"   <p>",
"    Application of an anesthetic cream (eg, EMLA) reduces the pain of the anesthetic injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/11\">",
"     11",
"    </a>",
"    ]. To be effective, EMLA should be applied by the patient to the anterior scrotum approximately one hour prior to the procedure. Wrapping the area (eg, plastic wrap) minimizes evaporation and facilitates absorption of the cream. Dosing is weight dependent and systemic toxicity (ie, methemoglobinemia) is unlikely if EMLA cream is applied correctly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8729?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\", section on 'Acquired methemoglobinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     VASECTOMY PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is reexamined just prior to the procedure to confirm the absence of unusual anatomy or other contraindication to the procedure. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Ideally, the procedure room should be warmed to 70 to 80 degrees Fahrenheit (20 to 25 degrees Celsius) which helps prevent contraction of the cremasteric and dartos muscles, facilitating isolation of the vas deferens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Equipment needed to perform a vasectomy includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32768?source=see_link\">",
"       Povidone iodine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"     </li>",
"     <li>",
"      Sterile drapes, sterile gloves, sterile gauze",
"     </li>",
"     <li>",
"      Electrocautery equipment or disposable thermal cautery",
"     </li>",
"     <li>",
"      Suture (4-0 absorbable [chromic or polyglactin 910] preferably on a non-cutting needle)",
"     </li>",
"     <li>",
"      10 mL syringe with a 1.5 inch 25 or 27 gauge needle for administering local anesthesia",
"     </li>",
"     <li>",
"      1 percent or 2 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      without epinephrine (maximum dose 4.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [2",
"      <span class=\"nowrap\">",
"       mg/pound])",
"      </span>",
"     </li>",
"     <li>",
"      Surgical instruments: vas fixation clamp and sharp dissecting forceps, straight scissors, needle holder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is asked to lie supine on the procedure table. It is helpful to position and secure the penis onto the lower abdomen (eg, with surgical drape, adhesive tape, or umbilical tape). The scrotum is then prepared with an antiseptic solution. Sterile towels are used to drape the area surrounding the scrotum, and sterile technique is employed for the remainder of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vas deferens is isolated and positioned to lie as superficially as possible beneath the median raphe of the scrotal skin anteriorly, midway between the top of the testes and the base of the penis. This is usually accomplished using the non-dominant hand and a \"three finger technique\" to manipulate the vas within the scrotum (",
"    <a class=\"graphic graphic_picture graphicRef78720 \" href=\"mobipreview.htm?32/25/33169\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Local anesthetic without epinephrine (0.5 to 1 mL) is injected into the skin to create a wheal over the vas. A large wheal is avoided because it will interfere with isolating the vas.",
"   </p>",
"   <p>",
"    Next, a vasal nerve block to anesthetize the deeper tissues can be performed in the following manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/13\">",
"     13",
"    </a>",
"    ]. With tension on the vas, the needle is advanced through the anesthetized scrotal skin approximately 2 to 3 cm along the sheath of the vas (but not into the vas) toward the inguinal ring, and 2 to 5 mL of anesthetic (depending on concentration) injected into the tissue surrounding the vas; there should not be any resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/13\">",
"     13",
"    </a>",
"    ]. Some operators then anesthetize the contralateral vas to allow ample time for the anesthetic to take effect.",
"   </p>",
"   <p>",
"    An alternate anesthetic method involves a no-needle jet injection technique that uses a high pressure spray to deliver local anesthetic through the scrotal skin and into the tissue surrounding the vas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The major drawback seems to be the initial cost of the device.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Exposing the vas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vas is positioned under the skin wheal as superficial to the skin as possible and a vas fixation clamp is used to gently entrap the vas and a minimal amount of overlying tightly stretched skin.",
"   </p>",
"   <p>",
"    In the conventional technique, a small incision is made and carried through the skin and subcutaneous tissue to expose the vas (",
"    <a class=\"graphic graphic_picture graphicRef55770 \" href=\"mobipreview.htm?8/21/8529\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For the no-scalpel technique, a sharp mosquito hemostat is used to puncture through the scrotal skin with care not to go through the vas. An opening approximately twice the width of the vas is made by gently spreading with both tips of the hemostat.",
"   </p>",
"   <p>",
"    If a vas fixating clamp is in place, it can be left alone or repositioned as needed. If the vas has not been fixed in a clamp, it should now be grasped. The vas is elevated through the incision or opening with an Allis clamp, towel clamp or dissecting forceps (",
"    <a class=\"graphic graphic_picture graphicRef53549 \" href=\"mobipreview.htm?14/36/14914\">",
"     picture 3",
"    </a>",
"    ). The perivasal tissue is incised an separated (",
"    <a class=\"graphic graphic_picture graphicRef68870 \" href=\"mobipreview.htm?6/62/7137\">",
"     picture 4",
"    </a>",
"    ); then, approximately two centimeters of the vas is brought up as a loop gently and grasped with a second vas fixating clamp, towel clip or ring forceps (",
"    <a class=\"graphic graphic_picture graphicRef74357 \" href=\"mobipreview.htm?9/52/10049\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The loop of vas is cleaned of residual tissue with care to avoid trauma to the associated blood vessels. The tip of a hemostat or tips of the dissecting forceps are inserted into the window of the vas deferens loop and gently spreading to completely isolate the vas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dividing the vas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vas is divided. The minimum length, if any, of vas that should be removed to prevent recanalization is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Rates of recanalization more likely reflect the technique used to manage the vasal ends than the actual length of the segment removed. We favor excision of a segment 10 to 15 mm in length. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Managing the vasal ends'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If a segment is removed, it can be sent for pathologic confirmation. Although this practice has little clinical benefit, histologic documentation that full thickness vas was excised can be helpful in the event of vasectomy failure. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Vasectomy failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Irrigation of the prostatic end does not have any documented benefit. Three randomized trials failed to demonstrate any acceleration of sperm clearance by irrigation of the prostatic end during vasectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Managing the vasal ends",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal method of managing the testicular vasal end is debated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/21-27\">",
"     21-27",
"    </a>",
"    ]. Several acceptable methods of occluding the vasal ends can be used, but in general, using ligatures or clips should be avoided. Intraluminal fulguration of 1.5 cm of the prostatic end of the vas with fascial interposition between the prostatic and testicular vasal ends appears to be the most effective method for managing the vasal ends [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/3,21-23,28-30\">",
"     3,21-23,28-30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Vasectomy failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Fulguration using a battery powered hand held cautery (red-hot wire) appears to scar and occlude the vas lumen more effectively than electrocautery (",
"    <a class=\"graphic graphic_picture graphicRef61651 \" href=\"mobipreview.htm?33/23/34161\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/28\">",
"     28",
"    </a>",
"    ]. Fascial interposition creates a tissue barrier between the vasal ends. Absorbable suture or a clip is used to tack a layer of the vas sheath between the two cut vasal ends (",
"    <a class=\"graphic graphic_picture graphicRef61651 \" href=\"mobipreview.htm?33/23/34161\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62120 \" href=\"mobipreview.htm?36/60/37839\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of the combined approach (fulguration and fascial interposition) was illustrated in a study of the outcome of 6248 vasectomies performed using fascial interposition in conjunction with thermal cautery of both ends (",
"    <a class=\"graphic graphic_picture graphicRef70870 \" href=\"mobipreview.htm?24/59/25520\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66760 \" href=\"mobipreview.htm?37/63/38910\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/31\">",
"     31",
"    </a>",
"    ]. No failures (ie, pregnancies) occurred and there was a low rate of complications (congestive epididymitis in 4.8 percent, sperm granuloma in 1.4 percent). Of note, the surgeons did not remove a vas segment or apply ligatures or clips to the open vasal ends.",
"   </p>",
"   <p>",
"    Ligation alone of the vasal ends should be avoided. A review of six studies that assessed this method (ie, \"cut and tie vasectomy\") reported failure rates of 1 to 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/32\">",
"     32",
"    </a>",
"    ]. Failure may have been due to ischemic sloughing of the vasal ends, which increases the potential for spontaneous recanalization.",
"   </p>",
"   <p>",
"    Conventional wisdom suggests that both vasal ends should be occluded by fulguration, ligation, or clips; however, some advocate leaving the testicular end untreated (open-ended vasectomy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. The rationale for leaving one end open is that sperm leakage from the testicular cut end prevents inspissation, increased epididymal pressure, and epididymal rupture and allows a small sperm granuloma to form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of this approach is supported by a study of 4330 open-ended and 3867 standard vasectomies (segment excised, cautery of both cut surfaces, ligation of both ends, fascial interposition) that found lower rates of complications with the open ended approach: congestive epididymitis (1.2 versus 2.7 percent), painful sperm granuloma (1.5 versus 3.2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/34\">",
"     34",
"    </a>",
"    ]. There were no significant differences between techniques in the rates of spontaneous recanalization (0.02 versus 0.08 percent).",
"   </p>",
"   <p>",
"    The open-ended technique can be offered to the patient. However, in our experience, most men choose to have both ends occluded. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Sperm granuloma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perivasal tissues are carefully inspected for bleeding and gently returned to the scrotum. If the incisional approach is used, one to two absorbable sutures are placed in the scrotal skin. In the no-scalpel technique, skin closure is not necessary. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the procedure is completed, we dress the wound with antibiotic ointment and a bandage. A fluff dressing is placed and the patient assisted in putting on a scrotal support or alternately, tight-fitting underwear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dressing and scrotal support are maintained for at least 48 hours after surgery. An ice pack intermittently applied to the scrotum for 48 hours also helps decrease discomfort and swelling.",
"   </p>",
"   <p>",
"    Significant post-procedure pain is common occurring in up to 30 percent of patients but is usually self limited.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    usually provides sufficient analgesia, although occasionally narcotic analgesics are necessary.",
"   </p>",
"   <p>",
"    Postoperative instructions should be reviewed with the patient. Mild pain, swelling, and bruising are normal for the first two to three days and blood in the ejaculate is common and will typically clear after three to four days. The patient should call for increasing pain, bleeding from the incision site, fever, or significant scrotal swelling.",
"   </p>",
"   <p>",
"    Bed rest or quiet activity is recommended for the first 24 hours following a vasectomy. The patient may return to light work in two to three days, but should refrain from heavy work, sports, or lifting for one week.",
"   </p>",
"   <p>",
"    Sexual activity is avoided for one week. The patient and his partner should be reminded to use an alternate method of contraception until semen analysis has confirmed absence of sperm (azoospermia) in the ejaculate. Since sperm are stored along the entire vas deferens and in the seminal vesicle, interruption of the vas does not result in immediate sterility and several ejaculations are required to evacuate all of the sperm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications following vasectomy include hematoma, infection, sperm granuloma, and persistent post vasectomy pain. The most important determinant of postoperative complications is operator experience. In one study, surgeons performing more than 50 vasectomies during the year studied had one-third the complication rate of those performing fewer than 10 procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematoma formation is the most common complication associated with vasectomy. In rare cases, bleeding may be severe enough to require reoperation for scrotal exploration, hematoma evacuation, and control of bleeding. The most common site of bleeding is the pampiniform plexus of veins.",
"   </p>",
"   <p>",
"    Hematoma rates are lower for no-scalpel procedures, where tissue dissection is minimized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/29,38\">",
"     29,38",
"    </a>",
"    ]. Hematoma formation occurs in 0.1 to 2.1 percent of men undergoing no-scalpel procedures compared with 0.3 to 10.7 percent for incisional technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials comparing no-scalpel and conventional incisional techniques also demonstrate lower wound infection rates for no-scalpel procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/29,38\">",
"     29,38",
"    </a>",
"    ]. Infections rates reported for the no-scalpel and incisional techniques are 0.2 to 0.9 and 1.3 to 4 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Sperm granuloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sperm are highly antigenic and stimulate a significant inflammatory reaction. A sperm granuloma may form when sperm leaks from the testicular side of an open-ended vas following vasectomy. Less commonly, they may form with extravasation from a cauterized or fulgurated vas.",
"   </p>",
"   <p>",
"    These granulomas are rarely symptomatic and may be protective to the testis and epididymis. The granuloma is rich in epithelial-lined channels that may vent leaking sperm away from the epididymis and protect against increased intraepididymal pressure.",
"   </p>",
"   <p>",
"    Most granulomas are asymptomatic and over time will ultimately resorb. Granulomas, however, have been implicated in increased rates of post-vasectomy pain and in vas recanalization related to the inflammatory response induced by the antigenic reaction to sperm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Post-vasectomy pain syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The post-vasectomy pain syndrome is distinct from post-procedure pain, however, there is some controversy regarding its definition, and therefore prevalence. Historically, rates for the post-vasectomy pain syndrome have been reported as very low (&lt;1 percent). However, surveys have found that the incidence of \"troublesome\" post-vasectomy pain is reported by about 15 percent of men, with pain severe enough to impact quality of life in 2 percent; survey respondents, however, may not have been representative of all post-vasectomy men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/41-44\">",
"     41-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of most post-vasectomy pain syndromes is a chronic congestive epididymitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/41\">",
"     41",
"    </a>",
"    ]. Testicular fluid and sperm production remain constant following vasectomy. The majority of this fluid accumulates in the epididymis, which then swells. While asymptomatic in most men, some will develop a chronic dull ache in the testes, which is made worse by ejaculation. Other causes or contributors to pain syndromes include the formation of sperm granuloma, or nerve entrapment at the vasectomy site.",
"   </p>",
"   <p>",
"    First-line therapy for postvasectomy pain is the administration of nonsteroidal antiinflammatory medications and warm baths. If unsuccessful, local nerve blocks or steroid injections may be performed by a pain specialist. If the post-vasectomy patient's discomfort is localized to a tender, palpable granuloma, this may be excised, followed by fulguration of the leaking end of the vas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Refractory cases may require surgery, including either vasectomy reversal (vasovasostomy) or complete epididymectomy. Vasovasostomy successfully relieves pain in up to 70 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/46\">",
"     46",
"    </a>",
"    ]. These patients, however, will almost always require the use of another form of contraception as a result. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39893?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of vasectomy\", section on 'Vasectomy reversal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complete epididymal resection is reserved for the most severe cases. Injury to the testicular blood supply, a known complication of this procedure, causes testicular atrophy. Thirty to ninety percent of patients undergoing epididymectomy for post-vasectomy orchialgia will have residual scrotal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Vasectomy failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasectomy failure can be due to technical errors, recanalization, or unprotected intercourse before azoospermia is documented.",
"   </p>",
"   <p>",
"    The varying techniques employed in vasectomy to fulgurate, ligate and manage the vasal ends are associated with different failure rates. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Vasectomy procedure'",
"    </a>",
"    above.) Representative failure rates are listed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraluminal needle cautery (vas not transected, no segment removed): Less than 1 percent",
"     </li>",
"     <li>",
"      Cautery both ends and fascial interruption: 1.2 percent or less",
"     </li>",
"     <li>",
"      Cautery (prostatic end) only and fascial interruption (clip): 0.02 to 2.4 percent",
"     </li>",
"     <li>",
"      Cautery of both ends and excision of a segment: 4.8 percent or less",
"     </li>",
"     <li>",
"      Ligation and fascial interruption: 16.7 percent or less",
"     </li>",
"     <li>",
"      Ligation and excision of segment: 1.5 to 29 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recanalization is rare, occurring in about 0.2 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/40\">",
"     40",
"    </a>",
"    ]. It is defined as the presence of any spermatozoa after one or more previously azoospermic samples were properly collected and documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/49\">",
"     49",
"    </a>",
"    ]. It can occur at any time following vasectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     FOLLOW UP TO CONFIRM STERILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review found that approximately 80 percent of patients are azoospermic after three months and 20 ejaculations, and the authors suggest that a single sample is sufficient to confirm sterility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/50\">",
"     50",
"    </a>",
"    ]. The time to achieve azoospermia declines with increasing number of ejaculations following vasectomy, and increases with patient age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. A coital frequency of at least three times per week seems to be associated with more rapid clearance, regardless of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest obtaining a semen analysis three months postoperatively; the patient should have had at least 20 ejaculates since the time of vasectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Azoospermia in a semen sample is definitive evidence of infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/50\">",
"     50",
"    </a>",
"    ]. The laboratory performing the analysis should examine a fresh specimen using direct microscopy; if sperm are not seen on the initial prepared slide, a centrifuged specimen should be evaluated. A systematic review including 56 studies reported the time to achieve azoospermia was variable, but more than 80 percent of men were azoospermic after three months and 20 ejaculations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/50\">",
"     50",
"    </a>",
"    ]. Although an at-home test is available that allows the patient to monitor sperm count after vasectomy, we recommend formal laboratory testing to confirm any results prior to assuming sterility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there are motile sperm at the three month check-up, a follow-up test is performed one to two months later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/58\">",
"     58",
"    </a>",
"    ]. Vasectomy is considered a failure if motile sperm are confirmed on the follow up examination, there have been a sufficient number of ejaculations (&gt;20) and &gt;3 months have elapsed since the procedure. The patient should be advised to use alternative contraception and potentially undergo a second procedure. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Vasectomy failure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Azoospermia is the ideal end point of vasectomy. A small proportion of patients, however, do not achieve azoospermia but consistently have nonmotile sperm. Nonmotility is a less definitive sign of infertility than azoospermia since it may reflect death of recently motile sperm due to a prolonged delay between ejaculation and laboratory analysis. The accuracy of determining whether sperm have normal motility is dependent on the timely examination of the semen specimen, ideally less than four hours from the time collected by the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/55\">",
"     55",
"    </a>",
"    ]. When rare, non-motile sperm are observed, a repeat test in another one to two months may show azoospermia or continued presence of rare, non-motile sperm.",
"   </p>",
"   <p>",
"    The continued presence of rare, non-motile sperm is probably clinically insignificant, and these men can be given cautious assurance of success. Guidelines from the British Andrology Society recommend that patients be given \"special clearance\" to discontinue other contraception, following appropriate counseling, provided they have: a low sperm count",
"    <span class=\"nowrap\">",
"     (&lt;10,000/mL),",
"    </span>",
"    all sperm are immotile, seven months have elapsed from vasectomy and there have been a minimum of 24 ejaculations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44712/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36242?source=see_link\">",
"       \"Patient information: Vasectomy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/2/29730?source=see_link\">",
"       \"Patient information: Vasectomy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasectomy, a safe and reliable outpatient procedure, is the most common method for permanent male contraception. Patients should be thoroughly counseled about the permanence of the procedure, potential risks and benefits, failure rates, and alternatives. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Patient counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Methods of vasal occlusion (microsurgical vasal plug, polymer injection) seek to provide a reversible mode of contraception for men. These methods are still largely investigational.",
"     </li>",
"     <li>",
"      Congenital or acquired anatomic abnormalities (eg, large varicocele, cryptorchidism), infection, and bleeding diathesis represent some contraindications to vasectomy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To perform vasectomy, the vas is isolated and brought up through a scrotal skin incision (conventional) or puncture site (no-scalpel technique). The vas is transected, a segment removed, and the prostatic end fulgurated. The testicular end is handled variably. A fascial interposition is created to isolate the vasal ends from each other. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Vasectomy procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a no-scalpel approach over conventional vasectomy because of lower bleeding and infection rates (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Vasectomy procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest fulguration and fascial interposition to manage the vasal ends (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Vasectomy procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postoperative care includes scrotal support, intermittent ice application, and rest. Sexual activity should be avoided for at least one week and contraception advised until azoospermia confirmed. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Postoperative care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematoma is the most common complication of vasectomy. Patients are advised to be seen if they experience significant swelling, bleeding from the vasectomy site, or pain not responding to analgesics. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Semen analysis is performed three months after the procedure. Azoospermia is indicative of a successful procedure. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Follow up to confirm sterility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/1\">",
"      Lohiya NK, Manivannan B, Mishra PK, Pathak N. Vas deferens, a site of male contraception: an overview. Asian J Androl 2001; 3:87.",
"     </a>",
"    </li>",
"    <li>",
"     www.engenderhealth.org/pubs/family-planning/vasectomy.php (Accessed on May 27, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/3\">",
"      Aradhya KW, Best K, Sokal DC. Recent developments in vasectomy. BMJ 2005; 330:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/4\">",
"      Peterson HB, Curtis KM. Clinical practice. Long-acting methods of contraception. N Engl J Med 2005; 353:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/5\">",
"      Li SQ, Goldstein M, Zhu J, Huber D. The no-scalpel vasectomy. J Urol 1991; 145:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/6\">",
"      Soebadi DM, Gardjito W, Mensink HJ. Intravasal injection of formed-in-place medical grade silicone rubber for vas occlusion. Int J Androl 1995; 18 Suppl 1:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/7\">",
"      Mruk DD. New perspectives in non-hormonal male contraception. Trends Endocrinol Metab 2008; 19:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/8\">",
"      Guha SK, Singh G, Ansari S, et al. Phase II clinical trial of a vas deferens injectable contraceptive for the male. Contraception 1997; 56:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/9\">",
"      Chaki SP, Das HC, Misro MM. A short-term evaluation of semen and accessory sex gland function in phase III trial subjects receiving intravasal contraceptive RISUG. Contraception 2003; 67:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/10\">",
"      Seenu V, Hafiz A. Routine antibiotic prophylaxis is not necessary for no scalpel vasectomy. Int Urol Nephrol 2005; 37:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/11\">",
"      Cooper TP. Use of EMLA cream with vasectomy. Urology 2002; 60:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/12\">",
"      Hahn IH, Hoffman RS, Nelson LS. EMLA-induced methemoglobinemia and systemic topical anesthetic toxicity. J Emerg Med 2004; 26:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/13\">",
"      Li PS, Li SQ, Schlegel PN, Goldstein M. External spermatic sheath injection for vasal nerve block. Urology 1992; 39:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/14\">",
"      Weiss RS, Li PS. No-needle jet anesthetic technique for no-scalpel vasectomy. J Urol 2005; 173:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/15\">",
"      White MA, Maatman TJ. Comparative analysis of effectiveness of two local anesthetic techniques in men undergoing no-scalpel vasectomy. Urology 2007; 70:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/16\">",
"      Kaplan KA, Huether CA. A clinical study of vasectomy failure and recanalization. J Urol 1975; 113:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/17\">",
"      Labrecque M, Hoang DQ, Turcot L. Association between the length of the vas deferens excised during vasectomy and the risk of postvasectomy recanalization. Fertil Steril 2003; 79:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/18\">",
"      Mason RG, Dodds L, Swami SK. Sterile water irrigation of the distal vas deferens at vasectomy: does it accelerate clearance of sperm? A prospective randomized trial. Urology 2002; 59:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/19\">",
"      Eisner B, Schuster T, Rodgers P, et al. A randomized clinical trial of the effect of intraoperative saline perfusion on postvasectomy azoospermia. Ann Fam Med 2004; 2:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/20\">",
"      Pearce I, Adeyoju A, Bhatt RI, et al. The effect of perioperative distal vasal lavage on subsequent semen analysis after vasectomy: a prospective randomized controlled trial. BJU Int 2002; 90:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/21\">",
"      Chen-Mok M, Bangdiwala SI, Dominik R, et al. Termination of a randomized controlled trial of two vasectomy techniques. Control Clin Trials 2003; 24:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/22\">",
"      Cook LA, Van Vliet H, Lopez LM, et al. Vasectomy occlusion techniques for male sterilization. Cochrane Database Syst Rev 2007; :CD003991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/23\">",
"      Esho JO, Cass AS. Recanalization rate following methods of vasectomy using interposition of fascial sheath of vas deferens. J Urol 1978; 120:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/24\">",
"      Sokal D, Irsula B, Chen-Mok M, et al. A comparison of vas occlusion techniques: cautery more effective than ligation and excision with fascial interposition. BMC Urol 2004; 4:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/25\">",
"      Li SQ, Xu B, Hou YH, et al. Relationship between vas occlusion techniques and recanalization. Adv Contracept Deliv Syst 1994; 10:153.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.auanet.org/content/media/vasectomy.pdf (Accessed on April 09, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/27\">",
"      Sharlip ID, Belker AM, Honig S, et al. Vasectomy: AUA guideline. J Urol 2012; 188:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/28\">",
"      Schmidt SS, Minckler TM. The vas after vasectomy: comparison of cauterization methods. Urology 1992; 40:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/29\">",
"      Sokal D, McMullen S, Gates D, Dominik R. A comparative study of the no scalpel and standard incision approaches to vasectomy in 5 countries. The Male Sterilization Investigator Team. J Urol 1999; 162:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/30\">",
"      Reynolds RD. Vas deferens occlusion during no-scalpel vasectomy. J Fam Pract 1994; 39:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/31\">",
"      Schmidt SS. Vasectomy by section, luminal fulguration and fascial interposition: results from 6248 cases. Br J Urol 1995; 76:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/32\">",
"      Denniston GC. Vasectomy by electrocautery: outcomes in a series of 2,500 patients. J Fam Pract 1985; 21:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/33\">",
"      Labrecque M, Nazerali H, Mondor M, et al. Effectiveness and complications associated with 2 vasectomy occlusion techniques. J Urol 2002; 168:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/34\">",
"      Errey BB, Edwards IS. Open-ended vasectomy: an assessment. Fertil Steril 1986; 45:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/35\">",
"      Denniston GC, Kuehl L. Open-ended vasectomy: approaching the ideal technique. J Am Board Fam Pract 1994; 7:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/36\">",
"      Shapiro EI, Silber SJ. Open-ended vasectomy, sperm granuloma, and postvasectomy orchialgia. Fertil Steril 1979; 32:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/37\">",
"      Kendrick JS, Gonzales B, Huber DH, et al. Complications of vasectomies in the United States. J Fam Pract 1987; 25:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/38\">",
"      Christensen P, al-Aqidi OA, Jensen FS, D&oslash;rflinger T. [Vasectomy. A prospective, randomized trial of vasectomy with bilateral incision versus the Li vasectomy]. Ugeskr Laeger 2002; 164:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/39\">",
"      Cook LA, Pun A, van Vliet H, et al. Scalpel versus no-scalpel incision for vasectomy. Cochrane Database Syst Rev 2007; :CD004112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/40\">",
"      Awsare NS, Krishnan J, Boustead GB, et al. Complications of vasectomy. Ann R Coll Surg Engl 2005; 87:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/41\">",
"      Manikandan R, Srirangam SJ, Pearson E, Collins GN. Early and late morbidity after vasectomy: a comparison of chronic scrotal pain at 1 and 10 years. BJU Int 2004; 93:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/42\">",
"      McMahon AJ, Buckley J, Taylor A, et al. Chronic testicular pain following vasectomy. Br J Urol 1992; 69:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/43\">",
"      Leslie TA, Illing RO, Cranston DW, Guillebaud J. The incidence of chronic scrotal pain after vasectomy: a prospective audit. BJU Int 2007; 100:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/44\">",
"      Morris C, Mishra K, Kirkman RJ. A study to assess the prevalence of chronic testicular pain in post-vasectomy men compared to non-vasectomised men. J Fam Plann Reprod Health Care 2002; 28:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/45\">",
"      Schmidt SS. Spermatic grauloma: an often painful lesion. Fertil Steril 1979; 31:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/46\">",
"      Nangia AK, Myles JL, Thomas AJ JR. Vasectomy reversal for the post-vasectomy pain syndrome: a clinical and histological evaluation. J Urol 2000; 164:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/47\">",
"      Padmore DE, Norman RW, Millard OH. Analyses of indications for and outcomes of epididymectomy. J Urol 1996; 156:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/48\">",
"      Dassow P, Bennett JM. Vasectomy: an update. Am Fam Physician 2006; 74:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/49\">",
"      Alderman PM. The lurking sperm. A review of failures in 8879 vasectomies performed by one physician. JAMA 1988; 259:3142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/50\">",
"      Griffin T, Tooher R, Nowakowski K, et al. How little is enough? The evidence for post-vasectomy testing. J Urol 2005; 174:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/51\">",
"      Marshall S, Lyon RP. Variability of sperm disappearance from the ejaculate after vasectomy. J Urol 1972; 107:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/52\">",
"      Arango Toro O, Andolz Peitivi P, Llad&oacute; Carbonell C, et al. [Post-vasectomy semen in 313 males. Statistical analysis, medical aspects, legal implications]. Arch Esp Urol 1993; 46:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/53\">",
"      Marwood RP, Beral V. Disappearance of spermatozoa from ejaculate after vasectomy. Br Med J 1979; 1:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/54\">",
"      Spencer B, Charlesworth D. Factors determining the rate of disappearance of sperm from the ejaculate after vasectomy. Br J Surg 1976; 63:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/55\">",
"      Hancock P, McLaughlin E, British Andrology Society. British Andrology Society guidelines for the assessment of post vasectomy semen samples (2002). J Clin Pathol 2002; 55:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/56\">",
"      Barone MA, Nazerali H, Cortes M, et al. A prospective study of time and number of ejaculations to azoospermia after vasectomy by ligation and excision. J Urol 2003; 170:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44712/abstract/57\">",
"      Klotz KL, Coppola MA, Labrecque M, et al. Clinical and consumer trial performance of a sensitive immunodiagnostic home test that qualitatively detects low concentrations of sperm following vasectomy. J Urol 2008; 180:2569.",
"     </a>",
"    </li>",
"    <li>",
"     Sandlow, JI, Winfield, HN, Goldstein, M. Surgery of the scrotum and seminal vesicles. In: Campbell-Walsh Urology, 9th ed, Wein, A, Kavoussi, L, Novick, A, et al (Eds), Saunders, Philadelphia 2000. p.1098.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8094 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44712=[""].join("\n");
var outline_f43_42_44712=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vasal transection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Conventional vasectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - No-scalpel vasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vasal occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vasal injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SURGICAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATIENT COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VASECTOMY PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Materials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Exposing the vas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dividing the vas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Managing the vasal ends",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Sperm granuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Post-vasectomy pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Vasectomy failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      FOLLOW UP TO CONFIRM STERILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8094\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8094|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/8/129\" title=\"figure 1\">",
"      Spermatic cord cross sectional anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/60/37839\" title=\"figure 2\">",
"      Fulguration of vasal ends during vasectomy illustration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/63/38910\" title=\"figure 3\">",
"      Fascial interposition during vasectomy illustration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8094|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/25/33169\" title=\"picture 1\">",
"      Isolating and positioning the vas during vasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/21/8529\" title=\"picture 2\">",
"      Scrotal incision during vasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/36/14914\" title=\"picture 3\">",
"      Grasping the vas during vasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/62/7137\" title=\"picture 4\">",
"      Incising the fascia during vasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/52/10049\" title=\"picture 5\">",
"      Isolating the vas during vasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/23/34161\" title=\"picture 6\">",
"      Intraluminal fulgaration of the vas during vasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/59/25520\" title=\"picture 7\">",
"      Fascial interposition during vasectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39893?source=related_link\">",
"      Overview of vasectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/2/29730?source=related_link\">",
"      Patient information: Vasectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36242?source=related_link\">",
"      Patient information: Vasectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_42_44713="Panic disorder: Epidemiology, clinical manifestations, and diagnosis";
var content_f43_42_44713=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44713/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44713/contributors\">",
"     Wayne Katon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44713/contributors\">",
"     Paul Ciechanowski, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44713/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44713/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/42/44713/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/42/44713/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/42/44713/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H191515140\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panic attacks and panic disorder are common problems in both primary care and psychiatric patients. A patient with panic attacks may present with classic, discrete episodes of intense fear that begin abruptly and last for several minutes to an hour. Patients also often present with autonomic symptoms of a panic attack such as chest pain or shortness of breath &ndash; frequently precipitating an emergency room visit.",
"   </p>",
"   <p>",
"    In panic disorder, patients experience recurrent, unexpected panic attacks, and one month or more of at least one of the following: worry about future attacks, phobic avoidance of situations that could trigger an attack, or other change in behavior due to the attacks such as frequent medical or emergency room visits.",
"   </p>",
"   <p>",
"    Panic attacks are not usually difficult to diagnose, given a sufficiently high level of awareness. It should also be noted, though, that panic attacks can occur in other anxiety disorders. Recognition and treatment of common comorbidities, such as agoraphobia or depression, is also critical to achieving good clinical outcomes. Infrequent panic attacks can occur with other anxiety disorders; therefore, accurate differential diagnosis is essential. &nbsp;",
"   </p>",
"   <p>",
"    This topic will address the epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of panic disorder. The epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of agoraphobia are discussed separately. The treatment of panic disorder, and the epidemiology, manifestations, diagnosis, and treatment of other anxiety disorders, including agoraphobia, are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191515149\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 12-month and lifetime prevalence of panic disorder in the United States (US) population (age 15 to 54 years) was 2.7 percent and 4.7 percent, respectively, in a 2005 nationally representative study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/1\">",
"     1",
"    </a>",
"    ]. A systematic review of 13 European studies reported a 12-month prevalence rate of panic disorder of 1.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of panic disorder among primary care patients is approximately twice as high as in the general population with rates of 4 to 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Panic attacks (which can occur in disorders other than panic disorder) are much more common than panic disorder, occurring in up to one-third of individuals at some point in their lifetime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disorder is approximately twice as common in women as among men, with a 5 percent lifetime prevalence among women versus 2 percent among men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/9\">",
"     9",
"    </a>",
"    ]. There appears to be a bimodal distribution in the prevalence of panic disorder by age, with one peak in late adolescence (15 to 19 years old) and a second peak at later ages (35 to 50 years old). Patients who develop panic disorder in adolescence frequently develop depressive disorders or co-existing depression and anxiety during their early adult years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Panic disorder is frequently accompanied by comorbid psychiatric disorders. One third to one half of individuals with panic disorder meet DSM-IV-TR criteria for major depression at initial presentation while over 60 percent will have had one or more lifetime episodes of major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. The National Comorbidity Study found that other anxiety disorders, including social phobia, generalized anxiety disorder, and post-traumatic stress disorder also frequently co-occur with panic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with bipolar disorder and alcohol abuse have been shown to have relatively high panic disorder prevalence rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2409?source=see_link\">",
"     \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most studies have shown a higher likelihood of suicide attempts among people with panic disorder than in the general population [19-21]. A 2006 analysis of data from the National Comorbidity Survey, which studied a representative sample of US adults ages 15 to 54, found that panic disorder was associated with suicide attempts in the prior 12 months, controlling for sociodemographic and clinical factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/17\">",
"     17",
"    </a>",
"    ]. The Netherlands Mental Health Survey found that a diagnosis of one or more anxiety disorders, including panic disorder, was associated with a higher rate of subsequent suicidal ideation and suicide attempts after controlling for sociodemographic factors and psychiatric comorbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/18\">",
"     18",
"    </a>",
"    ]. The study also found that individuals with co-occurring anxiety and mood disorders had a higher likelihood of suicide attempts compared to those with a mood disorder alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/18\">",
"     18",
"    </a>",
"    ]. Another study found the association between panic disorder and suicidality to be explained by their association with comorbid major depression, personality disorders, or alcohol abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191517267\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of panic disorder fits a stress-diathesis model (ie, the combination of an underlying predisposition and life stress). Vulnerability factors include specific genetic factors, childhood adversity, and several personality traits, including anxiety sensitivity and neuroticism. Current stressful life events in association with one or more of these vulnerability factors often precipitate development of panic attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1041967\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several lines of research indicate a genetic component to the disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First degree relatives of patients with panic disorder have been shown to meet criteria for the disorder in 18 to 41 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/23-25\">",
"       23-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Twin studies have shown higher concordance for monozygotic compared to dizygotic twins (31 percent and 0 percent, respectively, in one study) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/26\">",
"       26",
"      </a>",
"      ]. Twin studies have suggested a heritability of approximately 40 percent with contributions of 10 percent from common familial environment and greater than 50 percent from individual-specific environmental effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Linkage studies in families that have panic disorder have been hindered by non-replication and small numbers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/28\">",
"       28",
"      </a>",
"      ]. Genetic linkage studies have suggested that chromosomal regions 13q, 14q, 22q, 4q31-34, and probably 9q31 are associated with panic disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/29\">",
"       29",
"      </a>",
"      ]. A meta-analysis has implicated the Val158Met polymorphism of the catechol-0-methyltransferase gene in susceptibility to panic disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/30\">",
"       30",
"      </a>",
"      ]. The specific role of this genetic variation in patients with panic disorder needs further study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1041981\">",
"    <span class=\"h2\">",
"     Temperament",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxious temperaments as measured by high neuroticism scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/31\">",
"     31",
"    </a>",
"    ] and anxiety sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/32\">",
"     32",
"    </a>",
"    ] have also been shown to be risk factors for development of panic disorder. Neuroticism is a personality trait that is associated with poor stress resilience and often manifests in greater reactivity to life stressors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/31\">",
"     31",
"    </a>",
"    ]. Anxiety sensitivity is a measure of fear of anxiety symptoms and catastrophic cognitions regarding bodily sensations (eg, rapid heartbeat may be misinterpreted as a heart attack). Anxiety sensitivity has been shown to be associated with both genetic and environmental factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Subjects high in anxiety sensitivity have been shown to be more likely to develop panic disorder after experiencing stressful life experiences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Research data suggest that a behavior trait, behavioral inhibition, which is likely a precursor to development of social phobia, may also explain how agoraphobia can develop in response to a fearful temperament [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1043287\">",
"    <span class=\"h2\">",
"     Childhood adversity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have shown that childhood adversity such as a history of physical or sexual abuse increases the risk of panic disorder in adult years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/37\">",
"     37",
"    </a>",
"    ]. Both asthma in childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] and smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/40,41\">",
"     40,41",
"    </a>",
"    ] have been shown to increase the risk for onset of panic disorder in adulthood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1042021\">",
"    <span class=\"h2\">",
"     Life stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panic attacks often occur at times of significant life stress. Controlled studies have found that individuals experiencing panic attacks have a higher frequency of stressful life events than controls, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Events connoting danger and threat [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Uncontrollable or undesirable events causing severely reduced self-esteem [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An accident, trauma, rape, assault, or physical illness (including endocrinologic changes, eg, hyperthyroidism).",
"     </li>",
"     <li>",
"      Severe illness or death in a friend or relative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191515157\">",
"    <span class=\"h2\">",
"     Neurobiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research into underlying possible causative biologic factors is gradually emerging and is described below. &nbsp;Several neuroanatomic areas as well as a number of neurotransmitters (serotonin, norepinephrine, and gamma-aminobutyric acid [GABA]) have become the focus of research into the pathophysiology of panic attacks and panic disorder. The figure describes the proposed neural circuitry of panic (",
"    <a class=\"graphic graphic_figure graphicRef58548 \" href=\"mobipreview.htm?36/20/37190\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Researchers have focused on specific areas in the amygdala or hypothalamus as the potential site of neural triggers for panic attacks, suggesting that patients may inherit specific brain areas that are hyperexcitable and make the patient susceptible to unprovoked panic symptoms when exposed to mild interoceptive stressors such as an increased heart or respiratory rate; affected individuals may have a sensitivity to a wide range of agents such as carbon dioxide, lactate, caffeine, yohimbine, cholecystokinin, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    , in provoking anxiety attacks in experimental situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Alternatively, cognitive researchers have suggested that catastrophic thoughts associated with minor somatic symptoms provoked by the above challenge agents cause panic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amygdala, a structure in the temporal lobe, has been posited to be an anxiety &ldquo;way station&rdquo; that integrates:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensory information from the environment via the thalamus and sensory cortex",
"     </li>",
"     <li>",
"      Stored memory of prior experience via the frontal cortex and hippocampus",
"     </li>",
"     <li>",
"      Efferent pathways to a variety of brain regions involved in a panic or anxiety response including the locus ceruleus, hypothalamus, periaqueductal grey (PAG) and parabrachial nucleus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/42,45\">",
"       42,45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies have also hypothesized that the dorsomedial",
"    <span class=\"nowrap\">",
"     hypothalamus/perifornical",
"    </span>",
"    <span class=\"nowrap\">",
"     (DMH/PeF)",
"    </span>",
"    region coordinates rapid mobilization of behavioral, autonomic, respiratory, and endocrinologic responses to stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/43\">",
"     43",
"    </a>",
"    ]. Rats with disrupted GABA inhibition in the",
"    <span class=\"nowrap\">",
"     DMH/PeF",
"    </span>",
"    exhibit panic-like responses to lactate infusion similar to patients with panic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decreased inhibitory signaling associated with abnormalities in the GABA system has also been posited as causing panic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients with panic disorder have been found to have increased benzodiazepine binding in the right lateral frontal gyrus and temporal cortex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/46\">",
"     46",
"    </a>",
"    ], but decreased binding in the left hippocampus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/47\">",
"     47",
"    </a>",
"    ]. Based on magnetic resonance scans, decreased GABA concentrations have been found in the occipital cortex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/48\">",
"     48",
"    </a>",
"    ], basal ganglia and anterior cingulate cortex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/49\">",
"     49",
"    </a>",
"    ] in patients with panic disorder compared to controls.",
"   </p>",
"   <p>",
"    Other biologic studies have implicated key differences in the brain neurobiologic fear system in patients with panic disorder compared to controls. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with panic disorder who were administered a respiratory stimulant,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/37/14933?source=see_link\">",
"       doxapram",
"      </a>",
"      , were shown to have a larger increase in amygdala and cingulate gyrus activity and a greater decrease in prefrontal cortex activity than control subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Magnetic resonance imaging studies have found reductions in volume of the amygdala [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/51\">",
"       51",
"      </a>",
"      ] and left temporal lobe in patients with panic disorder compared to controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies have shown elevated glucose uptake in the amygdala, hippocampus, midbrain, thalamus, caudal pons, medulla, and cerebrum as measured by positron emission tomography (PET) scan in patients with panic disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) data have shown an increasing grey matter volume in the insula and upper brain stem and a decrease in the anterior cingulate gyrus (ACC) in patients with panic disorder versus healthy controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study using quantitative PET image analysis found a marked reduction in the density of the serotonin type 1a receptor in the anterior and posterior cingulate areas in the midbrain raphe in patients with panic disorder compared to controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The insula and ACC are thought to translate bodily signals into emotional feelings and patients with panic often overestimate and catastrophize bodily signals. These two areas are hypothesized to be a possible neural substrate of hypersensitivity to bodily signals often seen in patients with panic disorder and a possible site for pharmacologic intervention as well as cognitive behavioral therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antidepressants may prevent panic attacks by enhancing 5-HT inhibition of the PAG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191515165\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1043226\">",
"    <span class=\"h2\">",
"     Panic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panic attacks are characterized by the sudden onset of intense apprehension, fear or terror, and by the abrupt development of specific somatic, cognitive, and affective symptoms (",
"    <a class=\"graphic graphic_table graphicRef79985 \" href=\"mobipreview.htm?28/55/29563\">",
"     table 1",
"    </a>",
"    ). In panic disorder, panic attacks lead to persistent concern or anxiety about possible recurrence and resulting changes in behavior, such as agoraphobia, hypochondriacal concerns, and high medical utilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1043514\">",
"    <span class=\"h2\">",
"     Somatic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatic symptoms of panic disorder often predominate in patients&rsquo; clinical presentations. In a study of 55 primary care patients with panic disorder, presenting complaints included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac &mdash; 39 percent (chest pain in 22 percent, tachycardia in 25 percent)",
"     </li>",
"     <li>",
"      Neurologic &mdash; 44 percent (headaches in 20 percent, dizziness in 18 percent, faintness and pseudoseizures in 9 percent)",
"     </li>",
"     <li>",
"      Gastrointestinal - 33 percent (epigastric pain in 15 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with a presenting symptom of chest pain, panic disorder is a common diagnosis, but the relationship between the disorder and general medical illnesses can be complex. A review of 38 studies found panic disorder to be present in 30 percent of patients presenting with chest pain and minimal or no coronary disease. However, panic disorder can also coexist with coronary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=see_link&amp;anchor=H37#H37\">",
"     \"Differential diagnosis of chest pain in adults\", section on 'Psychogenic/psychosomatic causes of chest pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1043233\">",
"    <span class=\"h2\">",
"     Agoraphobia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with panic attacks can develop agoraphobia &mdash; anxiety about and avoidance of places or situations that might precipitate a panic attack, such as being in a crowd, using public transportation, or being alone or in a distant place. The epidemiology, clinical manifestations, course, and diagnosis of agoraphobia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10488?source=see_link\">",
"     \"Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1043241\">",
"    <span class=\"h2\">",
"     Utilization of medical services",
"    </span>",
"    &nbsp;&mdash;&nbsp;With somatic symptoms often prominent in the presentation of a panic attack, most patients seek health care from a general medical rather than mental health clinician. In one study of 97 patients with panic disorder, 35 percent initially presented to their primary care clinician, 32 percent to a hospital emergency department, and only 26 percent to a mental health clinician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients who present to primary care physicians with unexplained medical symptoms meet DSM-IV-TR criteria for panic disorder. Patients with panic disorder are often unsatisfied with a negative general medical work-up and repeatedly seek care for continuing frightening symptoms. In one study, 40 of 57 patients (70 percent) saw an average of 10 clinicians before finally receiving a diagnosis of panic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/57\">",
"     57",
"    </a>",
"    ]. Other studies have shown that patients with panic disorder have significantly higher utilization of medical services (eg, consultation rates, specialty clinician referrals, emergency department visits, hospital admissions, medication prescription, and laboratory tests) compared to age- and gender-matched controls; their extensive use of resources often precedes the diagnosis of panic disorder by as long as ten years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data are consistent with several analyses from the Epidemiological Catchment Area data, which found that respondents with panic disorder had the highest likelihood among those with psychiatric or substance use disorders of high utilization of medical services when compared with controls without psychiatric illness (8.2 for men and 5.2 for women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Utilization of primary care services among patients with panic disorder is roughly three times that of the typical patient receiving health care in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5752412\">",
"    <span class=\"h2\">",
"     Substance use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panic disorder has been shown to have a relatively high prevalence among patients with bipolar disorder and alcohol abuse. Patients may use alcohol or sedative hypnotics in desperation to control symptoms of panic disorder. These agents have a short-lived anxiolytic action, but are subsequently associated with rebound exacerbation of anxiety and panic attacks when blood levels decline. In addition, coexisting alcohol abuse with recurrent withdrawal can lead to a kindling effect on central controls of the sympathetic nervous system, resulting in more frequent and severe panic attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2409?source=see_link\">",
"     \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1043138\">",
"    <span class=\"h2\">",
"     Medical comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both community-based and clinic-based studies have shown that respondents with panic disorder may have a higher prevalence of other medical disorders compared to controls including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/63\">",
"       63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Irritable bowel syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/64\">",
"       64",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Interstitial cystitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/65\">",
"       65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Migraine headaches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The previously reported association between mitral valve prolapse and panic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/67\">",
"     67",
"    </a>",
"    ] has been questioned because of inconsistent results and methodologic limitations in the supporting research, including flawed diagnostic criteria for mitral valve prolapse, which resulted in over-diagnosis of this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3476?source=see_link\">",
"     \"Mitral valve prolapse syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mitral valve prolapse may be encountered in patients with panic disorder, but is unlikely to be the cause of the panic symptoms; in such instances, the panic disorder should be treated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40297?source=see_link\">",
"     \"Psychotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data suggest that a history of panic attacks is associated with an increased risk of mortality due to vascular causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/69\">",
"     69",
"    </a>",
"    ]. In the observational Women's Health Initiative study, the occurrence of at least one full-blown panic attack over a six month period was associated with an increased incidence of coronary heart disease over a five year follow-up period (hazard ratio [HR] 4.2, 95% CI 1.8-10) among 3400 postmenopausal women. All-cause mortality was also increased (HR 1.75) and there was a trend toward an increased risk for stroke. The risk for coronary heart disease was intermediate for women reporting limited symptom panic episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191515174\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panic disorder is a recurrent or chronic disease in the majority of cases. A review of 16 studies of panic disorder diagnosed with modern psychiatric criteria found that most patients had improvement in panic symptoms over a period of 15 to 60 months, but few experienced complete resolution of the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/70\">",
"     70",
"    </a>",
"    ]. A large community-based study of panic disorder followed over a two-year course found that remission occurred in 64 percent of subjects with time to remission of 5.7 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/71\">",
"     71",
"    </a>",
"    ]. However, remission had not occurred in one year in 43 percent of those with panic disorder. Panic attacks recurred in 21 percent of those who had achieved remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Predictors of remission in the community-based trial were female gender, absence of ongoing life stressors, low initial frequency of attacks, and sub-threshold panic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/71\">",
"     71",
"    </a>",
"    ]. Other studies have found comorbid major depression, agoraphobia, and personality disorders to predict a poorer outcome in patients with panic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Panic disorder reduces the quality of life and function in affected patients and their families. Decrements in familial, social, and vocational functioning occur to a degree comparable to that seen with major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. In one study, the number of disability days taken by patients with anxiety disorders was significantly greater than in those with diabetes, cardiac disease, or renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both infrequent panic attacks and panic disorder are associated with higher medical utilization, in large part resulting from frightening physical symptoms such as chest pain, palpitations or dizziness, and increased functional impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/59,60,72\">",
"     59,60,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191515190\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111733780\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete psychiatric examination, including a medical history and thorough physical and neurologic examination to rule out organic causes of symptoms, will lead to an accurate diagnosis of panic disorder in most cases. The history taking process should begin in an open-ended manner and be unhurried. Interviewing family members can provide valuable information about current symptoms and precipitating events.",
"   </p>",
"   <p>",
"    Information should be elicited about current life stress, separations, recent deaths, patient concerns and fears, interpersonal problems, recent substance abuse, and use of medications. The patient should be asked about avoidance patterns that have developed since the onset of panic attacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111733787\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited laboratory testing, such as thyroid function tests, complete blood count, and a chemistry panel are sufficient in most uncomplicated cases. Other laboratory and radiological tests may be needed based on findings from the patient&rsquo;s history and physical exam. An electrocardiogram (and, at times, ambulatory Holter monitoring) is required for anyone with significant cardiovascular symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111733801\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A panic attack is defined by DSM-IV-TR as a discrete period of intense fear or discomfort accompanied by at least four of 13 cardiopulmonary, neurologic, psychiatric, autonomic, or gastrointestinal symptoms (",
"    <a class=\"graphic graphic_table graphicRef79985 \" href=\"mobipreview.htm?28/55/29563\">",
"     table 1",
"    </a>",
"    ). Symptoms typically start abruptly and reach a peak within ten minutes.",
"   </p>",
"   <p>",
"    DSM-IV-TR criteria for panic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/75\">",
"     75",
"    </a>",
"    ], shown in the table (",
"    <a class=\"graphic graphic_table graphicRef69780 \" href=\"mobipreview.htm?31/45/32475\">",
"     table 2",
"    </a>",
"    ), focus upon three areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent unexpected panic attacks",
"     </li>",
"     <li>",
"      At least one month of persistent concern or anxiety over the possibility of additional attacks",
"     </li>",
"     <li>",
"      A significant change in behavior in relation to the panic attacks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A diagnosis of panic disorder under DSM-IV-TR can specify the presence or absence of agoraphobia. Diagnostic criteria for agoraphobia are described in a table (",
"    <a class=\"graphic graphic_table graphicRef60377 \" href=\"mobipreview.htm?21/41/22171\">",
"     table 3",
"    </a>",
"    ). The co-occurrence of panic disorder and agoraphobia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10488?source=see_link\">",
"     \"Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9381794\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of panic disorder can overlap with manifestations of other psychiatric disorders and mimic a number of general medical conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426623788\">",
"    <span class=\"h3\">",
"     Somatization disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most difficult psychiatric diagnoses to differentiate from panic disorder is somatization disorder. Patients with both panic disorder and somatization disorder present with multiple unexplained physical symptoms. Many patients with somatization disorder also have comorbid panic attacks or disorder. In one study, for example, 32 of 78 women (41 percent) with somatization disorder also met criteria for panic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatization disorder occurs in patients with a high likelihood of developmental histories of physical, sexual, and emotional abuse, and emotional neglect. Patients with somatization disorder also have a lifetime history of responding to stressors with multiple unexplained physical symptoms and high utilization of medical services. Patients experiencing somatization disorder with a history of abuse and neglect may feel interpersonally powerless and as a result draw attention to their somatic symptoms. They may use these symptoms to avoid role responsibilities, avoid intimacy, or to obtain disability coverage, or to obtain prescribed medications and use them to regulate emotions (eg, opiates and benzodiazepines) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/42/44713/abstract/77\">",
"     77",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36535?source=see_link\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Identifying patients with concurrent somatization disorder requires questions regarding the existence of chronic somatization symptoms since adolescence, a family history of females with somatization disorder, a family history of males with antisocial personality disorder or substance abuse problems, chaotic family histories, childhood sexual or physical abuse or emotional neglect, and abuse of prescription drugs, street drugs, or alcohol.",
"   </p>",
"   <p>",
"    Treatment of panic disorder in patients with milder forms of somatization frequently leads to remission of both physical symptoms and the tendency to be hypochondriacal. In contrast, treatment of panic disorder in those with somatization disorder may only lead to a 30 to 40 percent reduction in somatic symptoms because of the development of chronic social stressors and maladaptive patterns of coping with stress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9381808\">",
"    <span class=\"h3\">",
"     Other mental disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;To meet criteria for panic disorder, symptoms of panic attacks must be distinguished from panic-like symptoms that occur as part of other mental disorders. At least some of the panic attacks should be spontaneous and should not be limited to the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Performances or social interactions, as in social anxiety disorder (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44744?source=see_link\">",
"       \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A specific situation, such as heights as in acrophobia",
"     </li>",
"     <li>",
"      Exposure to specific stimuli (such as dirt or germs) with resulting obsessions, as in obsessive compulsive disorder (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36564?source=see_link\">",
"       \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exposure to a stimulus associated with trauma, as in post-traumatic stress disorder (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=see_link\">",
"       \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9381815\">",
"    <span class=\"h3\">",
"     Stimulant abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overuse of caffeine as well as abuse of stimulant drugs such as cocaine and amphetamines can precipitate panic attacks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/5/17498?source=see_link&amp;anchor=H11#H11\">",
"     \"Benefits and risks of caffeine and caffeinated beverages\", section on 'Psychiatric'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36535?source=see_link&amp;anchor=H268753590#H268753590\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\", section on 'Types of drugs abused'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9381822\">",
"    <span class=\"h3\">",
"     General medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of organic etiologies should be considered prior to making the diagnosis of panic disorder. A number of conditions can mimic symptoms of panic attacks including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angina (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=see_link&amp;anchor=H8#H8\">",
"       \"Differential diagnosis of chest pain in adults\", section on 'Cardiovascular causes of chest pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arrhythmias (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=see_link&amp;anchor=H8#H8\">",
"       \"Differential diagnosis of chest pain in adults\", section on 'Cardiovascular causes of chest pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic obstructive pulmonary disease (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=see_link\">",
"       \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Temporal lobe epilepsy (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=see_link\">",
"       \"Localization-related (partial) epilepsy: Causes and clinical features\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary embolus (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Asthma (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=see_link\">",
"       \"Diagnosis of asthma in adolescents and adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperthyroidism (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26520?source=see_link\">",
"       \"Diagnosis of hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pheochromocytoma (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"       \"Clinical presentation and diagnosis of pheochromocytoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment side effects, eg, hypoglycemia in patients with diabetes, toxic serum",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14648?source=see_link\">",
"       aminophylline",
"      </a>",
"      concentrations in patients with asthma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=see_link\">",
"       \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11161?source=see_link\">",
"       \"Theophylline use in asthma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/10/13473?source=see_link\">",
"       \"Patient information: Panic disorder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1043128\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Panic attacks are characterized by the sudden onset of intense apprehension, fear or terror, and by the abrupt development of specific somatic, cognitive, and affective symptoms (",
"      <a class=\"graphic graphic_table graphicRef79985 \" href=\"mobipreview.htm?28/55/29563\">",
"       table 1",
"      </a>",
"      ). In panic disorder, panic attacks lead to persistent concern or anxiety about possible recurrence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      resulting changes in behavior, such as agoraphobia, hypochondriacal concerns, and high medical utilization. (See",
"      <a class=\"local\" href=\"#H191515165\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10488?source=see_link&amp;anchor=H897575#H897575\">",
"       \"Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prevalence of panic disorder in the United States population was 2.7 percent over 12 months and 4.7 percent lifetime in a 2005 nationally representative study. The prevalence in women is twice that of men. (See",
"      <a class=\"local\" href=\"#H191515149\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of panic disorder fits a stress-diathesis model. Vulnerability factors include specific genetic factors, childhood adversity, and several personality traits, including anxiety sensitivity and neuroticism. Current stressful life events in association with one or more of these vulnerability factors often precipitate development of panic attacks. (See",
"      <a class=\"local\" href=\"#H191517267\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The biological basis of panic disorder is not yet known, but functional imaging and other translational studies strongly suggest the involvement of fear circuitry (including the amygdala) in its pathogenesis. (See",
"      <a class=\"local\" href=\"#H191517267\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Somatic symptoms of panic disorder often predominate in patients&rsquo; clinical presentations. Cardiac symptoms, (eg, chest pain and tachycardia) are common, as are neurologic (eg, headaches and dizziness) and gastrointestinal (eg, epigastric pain) symptoms. (See",
"      <a class=\"local\" href=\"#H1043514\">",
"       'Somatic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with panic attacks can develop agoraphobia &mdash; anxiety about and avoidance of places or situations that might precipitate a panic attack, such as being in a crowd or using public transportation. Agoraphobic patients may also fear and avoid unfamiliar, distant places or being alone and without help should a panic attack occur (",
"      <a class=\"graphic graphic_table graphicRef60377 \" href=\"mobipreview.htm?21/41/22171\">",
"       table 3",
"      </a>",
"      ). Panic disorder can occur with or without agoraphobia. Agoraphobia also occurs independent of panic attacks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10488?source=see_link\">",
"       \"Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Panic disorder is a recurrent or chronic disease in the majority of cases. Predictors of remission include female gender, absence of ongoing life stressors, low initial frequency of attacks, and sub-threshold panic. (See",
"      <a class=\"local\" href=\"#H191515174\">",
"       'Course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to making a diagnosis of panic disorder, organic etiologies for symptoms of panic should be considered. Medical conditions that can mimic panic attacks include angina, arrhythmias, chronic obstructive pulmonary disease, temporal lobe epilepsy, pulmonary embolus, asthma, hyperthyroidism, and pheochromocytoma. Substances that may trigger or worsen panic disorder include excessive caffeine use or the use of other stimulants, including certain drugs of abuse. (See",
"      <a class=\"local\" href=\"#H9381794\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/1\">",
"      Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/2\">",
"      Goodwin RD, Faravelli C, Rosi S, et al. The epidemiology of panic disorder and agoraphobia in Europe. Eur Neuropsychopharmacol 2005; 15:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/3\">",
"      Leon AC, Olfson M, Broadhead WE, et al. Prevalence of mental disorders in primary care. Implications for screening. Arch Fam Med 1995; 4:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/4\">",
"      Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study. JAMA 1995; 274:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/5\">",
"      Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007; 146:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/6\">",
"      Katon W, Vitaliano PP, Russo J, et al. Panic disorder. Spectrum of severity and somatization. J Nerv Ment Dis 1987; 175:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/7\">",
"      Smoller JW, Pollack MH, Wassertheil-Smoller S, et al. Prevalence and correlates of panic attacks in postmenopausal women: results from an ancillary study to the Women's Health Initiative. Arch Intern Med 2003; 163:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/8\">",
"      Kessler RC, Chiu WT, Jin R, et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006; 63:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/9\">",
"      Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/10\">",
"      Vollrath M, Angst J. Outcome of panic and depression in a seven-year follow-up: results of the Zurich study. Acta Psychiatr Scand 1989; 80:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/11\">",
"      Breier A, Charney DS, Heninger GR. Major depression in patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1984; 41:1129.",
"     </a>",
"    </li>",
"    <li>",
"     Cloninger, CR, Martin, RL, Clayton, P. A blind follow-up and family study of anxiety neurosis:  Preliminary analyses of the St. Louis 500. In: Anxiety: New Research and Changing Concepts, Klein, DF, Rabkin, J (Eds), Raven, New York 1981. p.137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/13\">",
"      Raskin M, Peeke HV, Dickman W, Pinsker H. Panic and generalized anxiety disorders. Developmental antecedents and precipitants. Arch Gen Psychiatry 1982; 39:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/14\">",
"      Pariser SF, Jones BA, Pinta ER, et al. Panic attacks: diagnostic evaluations of 17 patients. Am J Psychiatry 1979; 136:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/15\">",
"      Katon W, Vitaliano PP, Russo J, et al. Panic disorder: epidemiology in primary care. J Fam Pract 1986; 23:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/16\">",
"      Kessler RC, Nelson CB, McGonagle KA, et al. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996; 66:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/17\">",
"      Goodwin RD, Roy-Byrne P. Panic and suicidal ideation and suicide attempts: results from the National Comorbidity Survey. Depress Anxiety 2006; 23:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/18\">",
"      Sareen J, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry 2005; 62:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/19\">",
"      Vickers K, McNally RJ. Panic disorder and suicide attempt in the National Comorbidity Survey. J Abnorm Psychol 2004; 113:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/20\">",
"      Finlay-Jones R, Brown GW. types of stressful life event and the onset of anxiety and depressive disorders. Psychol Med 1981; 11:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/21\">",
"      Roy-Byrne PP, Geraci M, Uhde TW. Life events and the onset of panic disorder. Am J Psychiatry 1986; 143:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/22\">",
"      Faravelli C. Life events preceding the onset of panic disorder. J Affect Disord 1985; 9:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/23\">",
"      COHEN ME, BADAL DW, KILPATRICK A, et al. The high familial prevalence of neurocirculatory asthenia (anxiety neurosis, effort syndrome). Am J Hum Genet 1951; 3:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/24\">",
"      Crowe RR, Noyes R, Pauls DL, Slymen D. A family study of panic disorder. Arch Gen Psychiatry 1983; 40:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/25\">",
"      Noyes R Jr, Clancy J, Crowe R, et al. The familial prevalence of anxiety neurosis. Arch Gen Psychiatry 1978; 35:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/26\">",
"      Torgersen S. Genetic factors in anxiety disorders. Arch Gen Psychiatry 1983; 40:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/27\">",
"      Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001; 158:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/28\">",
"      Martin EI, Ressler KJ, Binder E, Nemeroff CB. The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am 2009; 32:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/29\">",
"      Maron E, Hettema JM, Shlik J. Advances in molecular genetics of panic disorder. Mol Psychiatry 2010; 15:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/30\">",
"      Domschke K, Deckert J, O'donovan MC, Glatt SJ. Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/31\">",
"      Hettema JM, Neale MC, Myers JM, et al. A population-based twin study of the relationship between neuroticism and internalizing disorders. Am J Psychiatry 2006; 163:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/32\">",
"      Watt, M, Stewart, S. The role of anxiety sensitivity components in mediating the relationship between childhood exposure to parental dyscontrol and adult anxiety symptoms. J Psychopathol Behav Assess 2003; 25:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/33\">",
"      Stein MB, Jang KL, Livesley WJ. Heritability of anxiety sensitivity: a twin study. Am J Psychiatry 1999; 156:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/34\">",
"      Watt MC, Stewart SH, Cox BJ. A retrospective study of the learning history origins of anxiety sensitivity. Behav Res Ther 1998; 36:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/35\">",
"      Schmidt NB, Lerew DR, Jackson RJ. The role of anxiety sensitivity in the pathogenesis of panic: prospective evaluation of spontaneous panic attacks during acute stress. J Abnorm Psychol 1997; 106:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/36\">",
"      Essex MJ, Klein MH, Slattery MJ, et al. Early risk factors and developmental pathways to chronic high inhibition and social anxiety disorder in adolescence. Am J Psychiatry 2010; 167:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/37\">",
"      Kessler RC, Davis CG, Kendler KS. Childhood adversity and adult psychiatric disorder in the US National Comorbidity Survey. Psychol Med 1997; 27:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/38\">",
"      Hasler G, Gergen PJ, Kleinbaum DG, et al. Asthma and panic in young adults: a 20-year prospective community study. Am J Respir Crit Care Med 2005; 171:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/39\">",
"      Craske MG, Poulton R, Tsao JC, Plotkin D. Paths to panic disorder/agoraphobia: an exploratory analysis from age 3 to 21 in an unselected birth cohort. J Am Acad Child Adolesc Psychiatry 2001; 40:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/40\">",
"      Cosci F, Knuts IJ, Abrams K, et al. Cigarette smoking and panic: a critical review of the literature. J Clin Psychiatry 2010; 71:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/41\">",
"      Isensee B, Wittchen HU, Stein MB, et al. Smoking increases the risk of panic: findings from a prospective community study. Arch Gen Psychiatry 2003; 60:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/42\">",
"      Roy-Byrne PP, Craske MG, Stein MB. Panic disorder. Lancet 2006; 368:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/43\">",
"      Johnson PL, Truitt WA, Fitz SD, et al. Neural pathways underlying lactate-induced panic. Neuropsychopharmacology 2008; 33:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/44\">",
"      Clark DM. A cognitive approach to panic. Behav Res Ther 1986; 24:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/45\">",
"      Graeff FG, Del-Ben CM. Neurobiology of panic disorder: from animal models to brain neuroimaging. Neurosci Biobehav Rev 2008; 32:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/46\">",
"      Malizia AL, Cunningham VJ, Bell CJ, et al. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998; 55:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/47\">",
"      Bremner JD, Innis RB, Southwick SM, et al. Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. Am J Psychiatry 2000; 157:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/48\">",
"      Goddard AW, Mason GF, Appel M, et al. Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am J Psychiatry 2004; 161:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/49\">",
"      Ham BJ, Sung Y, Kim N, et al. Decreased GABA levels in anterior cingulate and basal ganglia in medicated subjects with panic disorder: a proton magnetic resonance spectroscopy (1H-MRS) study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/50\">",
"      Garakani A, Buchsbaum MS, Newmark RE, et al. The effect of doxapram on brain imaging in patients with panic disorder. Eur Neuropsychopharmacol 2007; 17:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/51\">",
"      Massana G, Serra-Grabulosa JM, Salgado-Pineda P, et al. Amygdalar atrophy in panic disorder patients detected by volumetric magnetic resonance imaging. Neuroimage 2003; 19:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/52\">",
"      Uchida RR, Del-Ben CM, Santos AC, et al. Decreased left temporal lobe volume of panic patients measured by magnetic resonance imaging. Braz J Med Biol Res 2003; 36:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/53\">",
"      Neumeister A, Bain E, Nugent AC, et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 2004; 24:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/54\">",
"      Katon W. Panic disorder and somatization. Review of 55 cases. Am J Med 1984; 77:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/55\">",
"      Fleet RP, Dupuis G, Marchand A, et al. Panic disorder, chest pain and coronary artery disease: literature review. Can J Cardiol 1994; 10:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/56\">",
"      Katerndahl DA, Realini JP. Where do panic attack sufferers seek care? J Fam Pract 1995; 40:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/57\">",
"      Sheehan DV. Current concepts in psychiatry. Panic attacks and phobias. N Engl J Med 1982; 307:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/58\">",
"      Simpson RJ, Kazmierczak T, Power KG, Sharp DM. Controlled comparison of the characteristics of patients with panic disorder. Br J Gen Pract 1994; 44:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/59\">",
"      Klerman GL, Weissman MM, Ouellette R, et al. Panic attacks in the community. Social morbidity and health care utilization. JAMA 1991; 265:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/60\">",
"      Simon GE, VonKorff M. Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area study. Am J Psychiatry 1991; 148:1494.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Public Health Service National Center for Health Statistics. National Medical Care Utilization and Expenditure Survey (NMCUES). Washington, DC: US Government Printing Office; November 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/62\">",
"      Post RM, Uhde TW, Putnam FW, et al. Kindling and carbamazepine in affective illness. J Nerv Ment Dis 1982; 170:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/63\">",
"      Davies SJ, Ghahramani P, Jackson PR, et al. Association of panic disorder and panic attacks with hypertension. Am J Med 1999; 107:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/64\">",
"      Walker EA, Katon WJ, Hansom J, et al. Psychiatric diagnoses and sexual victimization in women with chronic pelvic pain. Psychosomatics 1995; 36:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/65\">",
"      Weissman MM, Gross R, Fyer A, et al. Interstitial cystitis and panic disorder: a potential genetic syndrome. Arch Gen Psychiatry 2004; 61:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/66\">",
"      Zaubler TS, Katon, W. Panic disorder and medical comorbidity: A review of the medical and psychiatric literature. Bull Menninger Clin 1996; 60(2):A13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/67\">",
"      Katerndahl DA. Panic and prolapse. Meta-analysis. J Nerv Ment Dis 1993; 181:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/68\">",
"      Filho AS, Maciel BC, Mart&iacute;n-Santos R, et al. Does the association between mitral valve prolapse and panic disorder really exist? Prim Care Companion J Clin Psychiatry 2008; 10:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/69\">",
"      Smoller JW, Pollack MH, Wassertheil-Smoller S, et al. Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study. Arch Gen Psychiatry 2007; 64:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/70\">",
"      Roy-Byrne PP, Cowley DS. Course and outcome in panic disorder: a review of recent follow-up studies. Anxiety 1994; 1:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/71\">",
"      Batelaan NM, de Graaf R, Penninx BW, et al. The 2-year prognosis of panic episodes in the general population. Psychol Med 2010; 40:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/72\">",
"      Sherbourne, CD, Sullivan, G, Craske, MG, et, al. Functioning and disability levels in primary care out-patients with one or more anxiety disorders. Psychol Med 2010; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/73\">",
"      Katon W, Hollifield M, Chapman T, et al. Infrequent panic attacks: psychiatric comorbidity, personality characteristics and functional disability. J Psychiatr Res 1995; 29:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/74\">",
"      Sherbourne CD, Wells KB, Judd LL. Functioning and well-being of patients with panic disorder. Am J Psychiatry 1996; 153:213.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th, text revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/76\">",
"      Liskow B, Othmer E, Penick EC, et al. Is Briquet's syndrome a heterogeneous disorder? Am J Psychiatry 1986; 143:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/42/44713/abstract/77\">",
"      Katon W, Ries RK, Kleinman A. The prevalence of somatization in primary care. Compr Psychiatry 1984; 25:208.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14628 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44713=[""].join("\n");
var outline_f43_42_44713=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1043128\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191515140\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191515149\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191517267\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1041967\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1041981\">",
"      Temperament",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1043287\">",
"      Childhood adversity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1042021\">",
"      Life stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H191515157\">",
"      Neurobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191515165\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1043226\">",
"      Panic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1043514\">",
"      Somatic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1043233\">",
"      Agoraphobia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1043241\">",
"      Utilization of medical services",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5752412\">",
"      Substance use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1043138\">",
"      Medical comorbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191515174\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191515190\">",
"      ASSESSMENT AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111733780\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111733787\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111733801\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9381794\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H426623788\">",
"      - Somatization disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9381808\">",
"      - Other mental disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9381815\">",
"      - Stimulant abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9381822\">",
"      - General medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1043128\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14628\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14628|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/20/37190\" title=\"figure 1\">",
"      Neural circuitry of panic attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14628|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/55/29563\" title=\"table 1\">",
"      Criteria for panic attack",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/45/32475\" title=\"table 2\">",
"      Criteria for panic disorder without agoraphobia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/41/22171\" title=\"table 3\">",
"      DSM-IV-TR criteria for agoraphobia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10488?source=related_link\">",
"      Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2409?source=related_link\">",
"      Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/5/17498?source=related_link\">",
"      Benefits and risks of caffeine and caffeinated beverages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=related_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=related_link\">",
"      Hypoglycemia in adults without diabetes mellitus: Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3476?source=related_link\">",
"      Mitral valve prolapse syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36564?source=related_link\">",
"      Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/10/13473?source=related_link\">",
"      Patient information: Panic disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36535?source=related_link\">",
"      Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40297?source=related_link\">",
"      Psychotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44744?source=related_link\">",
"      Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11161?source=related_link\">",
"      Theophylline use in asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_42_44714="School action plan A";
var content_f43_42_44714=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59053%7EPULM%2F71869%7EPULM%2F51794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59053%7EPULM%2F71869%7EPULM%2F51794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    School asthma action plan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 771px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    School asthma action plan (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 702px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    School asthma action plan (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 777px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44714=[""].join("\n");
var outline_f43_42_44714=null;
var title_f43_42_44715="Testicular tumors";
var content_f43_42_44715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of testicular tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Germ cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Seminoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Seminoma with syncytiotrophoblastic cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Spermatocytic seminoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Spermatocytic seminoma with sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Nonseminomatous germ cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Embryonal carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Teratoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Dermoid cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Monodermal teratoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Teratoma with somatic type malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Trophoblastic tumors (choriocarcinoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Yolk sac tumor (endodermal sinus tumor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mixed germ cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sex cord-stromal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sertoli cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leydig cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulosa cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed types (eg, Sertoli-Leydig cell tumor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unclassified",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tumours of the Urinary System and Male Genital Organs. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (Eds). In: World Health Organization Classification of Tumours. Lyon 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44715=[""].join("\n");
var outline_f43_42_44715=null;
var title_f43_42_44716="Neurologic gait disorders in elderly patients";
var content_f43_42_44716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F82835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F82835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neurologic gait disorders in elderly patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"       <td class=\"subtitle1\">",
"        Characteristics of gait",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper motor neuron weakness",
"       </td>",
"       <td>",
"        The toes do not adequately clear the ground because the hip flexors are weak, and the toes scuff with each step. The strategy of circumduction at the hip helps with toe clearance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lower motor neuron weakness",
"       </td>",
"       <td>",
"        With lower motor neuron foot drop, the gait is high stepping because the hip flexors are strong and compensate for the weakness to allow foot clearance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myopathic weakness",
"       </td>",
"       <td>",
"        Waddling gait and abnormal pelvic tilt with each step because of limb girdle weakness.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spasticity",
"       </td>",
"       <td>",
"        Gait is narrow-based; the toes turn in and scrape on the floor with each step, producing a scuffing sound and wearing of the tips of the soles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deafferentation",
"       </td>",
"       <td>",
"        Classically, gait is high stepping and stamping, and may be slightly wide-based. Stride length is normal or a little reduced. The gait deteriorates markedly in the dark.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extrapyramidal",
"       </td>",
"       <td>",
"        Narrow-based gait&nbsp;with reduced stride length; the feet barely clear the floor. Posture is stooped&nbsp;and&nbsp;arm swing reduced&nbsp;when walking. The forward center of gravity causes increasingly faster, short steps (hurrying or \"festinating\"). Turning is by small steps rather than pivoting.&nbsp;Additional manifestations may include gait initiation difficulty, start hesitation, freezing, and retropulsion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebellar ataxia",
"       </td>",
"       <td>",
"        The gait may appear to be stumbling, lurching, staggering, reeling, drunken,&nbsp;or slow, with reduced step length and a&nbsp;wide base. Associated features can include other signs of ataxia, including scanning and slow speech, finger-nose and heel-shin dysmetria, and dyssynergia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vestibular dysfunction",
"       </td>",
"       <td>",
"        Deviation on walking to the side of the affected ear. The gait varies from an occasional stumble to frank veering. The legs are slightly spread, and stride length is slightly reduced. Stamping on the spot with eyes closed demonstrates veering (Unterberger test). Often associated with nystagmus.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frontal lobe dysfunction",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Cautious gait, a consequence of compensatory adjustments in response to real or perceived disequilibrium",
"         </li>",
"         <li>",
"          Isolated gait ignition failure, characterized by difficulty initiating or maintaining locomotion",
"         </li>",
"         <li>",
"          Frontal disequilibrium, characterized by inappropriate or counterproductive postural and locomotion responses",
"         </li>",
"         <li>",
"          Frontal gait disorder, characterized by variable base (narrow to wide), short shuffling steps, disequilibrium, and start and turn hesitation",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orthostatic myoclonus",
"       </td>",
"       <td>",
"        Leg jerking occurs while upright. The locomotion problem is variable, with either gait \"apraxia\" or gait initiation difficulty noted in approximately one-half of the patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychogenic",
"       </td>",
"       <td>",
"        Walking is bizarre and does not conform to any of the usual patterns. There may be excessive slowness and stiffness, or maintenance of postural control on a narrow base with flailing arms and excessive trunk sway.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confusional state",
"       </td>",
"       <td>",
"        Asterixis of the lower limbs may throw the patient to the floor. Inattention to task may lead to gait ataxia.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44716=[""].join("\n");
var outline_f43_42_44716=null;
var title_f43_42_44717="DDx ADHD in children";
var content_f43_42_44717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis for attention-deficit hyperactivity disorder in children and adolescents*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Methods to distinguish from ADHD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Developmental variations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intellectual disability",
"       </td>",
"       <td>",
"        Psychometric testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Giftedness",
"       </td>",
"       <td>",
"        Psychometric testing",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Normal variation",
"       </td>",
"       <td>",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Neurologic or developmental disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Learning disability",
"       </td>",
"       <td>",
"        Psychometric testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Language or communication disorder",
"       </td>",
"       <td>",
"        Psychometric testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autism spectrum disorders",
"       </td>",
"       <td>",
"        History; structured observation&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neurodevelopmental syndromes (eg, fetal alcohol syndrome, fragile X syndrome)",
"       </td>",
"       <td>",
"        History; examination; genetic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Seizure disorder",
"       </td>",
"       <td>",
"        History; electroencephalography if clinically indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sequelae of central nervous system trauma or infection",
"       </td>",
"       <td>",
"        History",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Motor coordination disorder",
"       </td>",
"       <td>",
"        History; examination; occupational therapy evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Emotional/behavioral disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Depression or mood disorder",
"       </td>",
"       <td>",
"        Broadband behavior scale; mental health evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anxiety disorder",
"       </td>",
"       <td>",
"        Broadband behavior scale; mental health evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oppositional defiant disorder",
"       </td>",
"       <td>",
"        Broadband behavior scale; mental health evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conduct disorder",
"       </td>",
"       <td>",
"        Broadband behavior scale; mental health evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obsessive compulsive disorder",
"       </td>",
"       <td>",
"        Broadband behavior scale; mental health evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Post-traumatic stress disorder",
"       </td>",
"       <td>",
"        Broadband behavior scale; mental health evaluation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Adjustment disorder",
"       </td>",
"       <td>",
"        Broadband behavior scale; mental health evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Psychosocial or environmental problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Child abuse or neglect",
"       </td>",
"       <td>",
"        Medical history; psychosocial history; examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stressful home environment",
"       </td>",
"       <td>",
"        Psychosocial history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inadequate or punitive parenting",
"       </td>",
"       <td>",
"        Psychosocial history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parental psychopathology or substance abuse",
"       </td>",
"       <td>",
"        Psychosocial history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inappropriate educational setting",
"       </td>",
"       <td>",
"        Symptoms occur at school but not at home",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Frequent school absence",
"       </td>",
"       <td>",
"        Psychosocial history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Selected medical conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hearing or vision impairment",
"       </td>",
"       <td>",
"        Hearing and vision screen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sleep disorder",
"       </td>",
"       <td>",
"        History; sleep study as indicated by clinical findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iron deficiency anemia",
"       </td>",
"       <td>",
"        Complete blood count and other hematologic studies as indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lead poisoning",
"       </td>",
"       <td>",
"        Measurement of blood lead level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endocrine disorders (eg, thyroid disease, diabetes mellitus)",
"       </td>",
"       <td>",
"        Laboratory studies as indicated by clinical findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiac disorders (eg, heart failure)",
"       </td>",
"       <td>",
"        Medical history; echocardiograph/pediatric cardiology consultation as indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Substance abuse",
"       </td>",
"       <td>",
"        History; toxicology screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Food allergy",
"       </td>",
"       <td>",
"        History; allergy testing as indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Undernutrition",
"       </td>",
"       <td>",
"        Assessment of growth parameters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medication side effects",
"       </td>",
"       <td>",
"        History",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADHD: Attention deficit hyperactivity disorder.",
"     <br>",
"      * These conditions may mimic or co-occur with attention deficit hyperactivity disorder.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4th ed, American Psychiatric Association, Washington, DC 2000. p.85.",
"       </li>",
"       <li>",
"        Leslie LK, Guevara JP. Attention-deficit/hyperactivity disorder. In: American Academy of Pediatrics Textbook of Pediatric Care, McInerny TK (Ed), American Academy of Pediatrics, Elk Grove Village, IL, 2009. p.1201.",
"       </li>",
"       <li>",
"        Subcommittee on attention-deficit/hyperactivity disorder, Steering committee on quality improvement and management. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics 2011: 128:1007.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44717=[""].join("\n");
var outline_f43_42_44717=null;
var title_f43_42_44718="Anticholinergic agents";
var content_f43_42_44718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Anticholinergic agents",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 424px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chemical structure of two naturally occurring tertiary ammonium compounds (atropine and scopolamine) and their synthetic quaternary derivatives (ipratropium and tiotropium). The ammonium group responsible for the difference in the properties of these compounds is at the top left corner of each structure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44718=[""].join("\n");
var outline_f43_42_44718=null;
var title_f43_42_44719="Advanced stasis dermatitis";
var content_f43_42_44719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Advanced stasis dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 228px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Advanced pigment changes of stasis dermatitis are characterized by red oozing skin (worse on the left anterior leg) with some scaling on the ankle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick C Alguire, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_42_44719=[""].join("\n");
var outline_f43_42_44719=null;
